NZ727129B2 - Immuno-modulatory progenitor (imp) cell - Google Patents
Immuno-modulatory progenitor (imp) cell Download PDFInfo
- Publication number
- NZ727129B2 NZ727129B2 NZ727129A NZ72712915A NZ727129B2 NZ 727129 B2 NZ727129 B2 NZ 727129B2 NZ 727129 A NZ727129 A NZ 727129A NZ 72712915 A NZ72712915 A NZ 72712915A NZ 727129 B2 NZ727129 B2 NZ 727129B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- cells
- population
- imp
- detectable levels
- receptor
- Prior art date
Links
- 230000002519 immonomodulatory Effects 0.000 title claims abstract description 14
- 210000004027 cells Anatomy 0.000 claims abstract description 453
- 230000001809 detectable Effects 0.000 claims abstract description 103
- 102100014035 CXCR1 Human genes 0.000 claims abstract description 41
- 101700011366 CXCR1 Proteins 0.000 claims abstract description 41
- 210000001772 Blood Platelets Anatomy 0.000 claims abstract description 39
- 102100003082 FASLG Human genes 0.000 claims abstract description 33
- 230000014509 gene expression Effects 0.000 claims abstract description 32
- 239000006166 lysate Substances 0.000 claims abstract description 31
- 102100016391 TLR9 Human genes 0.000 claims abstract description 28
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 25
- 239000001301 oxygen Substances 0.000 claims abstract description 20
- 102100014012 CXCR2 Human genes 0.000 claims abstract description 19
- 108090001007 Interleukin-8 Proteins 0.000 claims abstract description 18
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims abstract description 18
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims abstract description 18
- 101710025698 FASLG Proteins 0.000 claims abstract description 16
- 101710031679 HEXIM1 Proteins 0.000 claims abstract description 16
- 102100014085 S1PR1 Human genes 0.000 claims abstract description 16
- 102100016532 CD99 Human genes 0.000 claims abstract description 15
- 108060001253 CD99 Proteins 0.000 claims abstract description 15
- 102100005498 NRP1 Human genes 0.000 claims abstract description 15
- 101700048143 NRP1 Proteins 0.000 claims abstract description 15
- 101700061092 TLR9 Proteins 0.000 claims abstract description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 12
- 210000001185 Bone Marrow Anatomy 0.000 claims abstract description 10
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 10
- 238000003306 harvesting Methods 0.000 claims abstract description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims abstract description 5
- 210000001519 tissues Anatomy 0.000 claims description 99
- 102000005962 receptors Human genes 0.000 claims description 33
- 108020003175 receptors Proteins 0.000 claims description 33
- 102100010782 EGFR Human genes 0.000 claims description 25
- 101700039191 EGFR Proteins 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 24
- XKTZWUACRZHVAN-VADRZIEHSA-N Interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims description 18
- 230000000747 cardiac effect Effects 0.000 claims description 18
- 102000004890 Interleukin-8 Human genes 0.000 claims description 17
- 229940096397 Interleukin-8 Drugs 0.000 claims description 17
- 108010039471 Fas Ligand Protein Proteins 0.000 claims description 16
- 102100008185 IL6R Human genes 0.000 claims description 15
- 101710022769 IL6R Proteins 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 102000004207 Neuropilin-1 Human genes 0.000 claims description 13
- 108090000772 Neuropilin-1 Proteins 0.000 claims description 13
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 13
- 206010022114 Injury Diseases 0.000 claims description 11
- 206010061363 Skeletal injury Diseases 0.000 claims description 11
- 239000002502 liposome Substances 0.000 claims description 11
- 208000010125 Myocardial Infarction Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 210000000988 Bone and Bones Anatomy 0.000 claims description 9
- 206010007710 Cartilage injury Diseases 0.000 claims description 9
- 229940100601 Interleukin-6 Drugs 0.000 claims description 9
- 102000004889 Interleukin-6 Human genes 0.000 claims description 9
- 206010061223 Ligament injury Diseases 0.000 claims description 9
- 206010067125 Liver injury Diseases 0.000 claims description 9
- 208000004852 Lung Injury Diseases 0.000 claims description 9
- 206010061481 Renal injury Diseases 0.000 claims description 9
- 208000002459 Tendon Injury Diseases 0.000 claims description 9
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 9
- 230000000735 allogeneic Effects 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 9
- 200000000010 kidney injury Diseases 0.000 claims description 9
- 231100000515 lung injury Toxicity 0.000 claims description 9
- 210000004072 Lung Anatomy 0.000 claims description 8
- 208000000175 Nail-Patella Syndrome Diseases 0.000 claims description 6
- 206010007554 Cardiac failure Diseases 0.000 claims description 5
- 210000000845 Cartilage Anatomy 0.000 claims description 5
- 206010019280 Heart failure Diseases 0.000 claims description 5
- 210000003734 Kidney Anatomy 0.000 claims description 5
- 210000004185 Liver Anatomy 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 206010062624 High turnover osteopathy Diseases 0.000 claims description 4
- 206010020707 Hyperparathyroidism primary Diseases 0.000 claims description 4
- 210000003041 Ligaments Anatomy 0.000 claims description 4
- 206010031149 Osteitis Diseases 0.000 claims description 4
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 4
- 206010031150 Osteitis condensans Diseases 0.000 claims description 4
- 201000001146 Paget's disease of bone Diseases 0.000 claims description 4
- 210000002435 Tendons Anatomy 0.000 claims description 4
- 201000008975 bone inflammation disease Diseases 0.000 claims description 4
- 201000010934 exostosis Diseases 0.000 claims description 4
- 201000000981 primary hyperparathyroidism Diseases 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 206010061728 Bone lesion Diseases 0.000 claims description 3
- 206010017076 Fracture Diseases 0.000 claims description 3
- 210000003716 Mesoderm Anatomy 0.000 claims description 3
- 200000000023 metastatic cancer Diseases 0.000 claims description 3
- 201000008838 periodontal disease Diseases 0.000 claims description 3
- 206010003119 Arrhythmia Diseases 0.000 claims description 2
- 208000003432 Bone Disease Diseases 0.000 claims description 2
- 206010007521 Cardiac arrhythmias Diseases 0.000 claims description 2
- 208000001353 Coffin-Lowry Syndrome Diseases 0.000 claims description 2
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- 206010049889 Craniosynostosis Diseases 0.000 claims description 2
- 208000009283 Craniosynostosis Diseases 0.000 claims description 2
- 206010018720 Greenstick fracture Diseases 0.000 claims description 2
- 208000002907 Heart Valve Disease Diseases 0.000 claims description 2
- 206010049933 Hypophosphatasia Diseases 0.000 claims description 2
- 208000006541 Klippel-Feil Syndrome Diseases 0.000 claims description 2
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims description 2
- 206010027425 Metabolic bone disease Diseases 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- 208000002624 Osteitis Fibrosa Cystica Diseases 0.000 claims description 2
- 208000007656 Osteochondritis Dissecans Diseases 0.000 claims description 2
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims description 2
- 208000005368 Osteomalacia Diseases 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims description 2
- 206010031264 Osteonecrosis Diseases 0.000 claims description 2
- 206010049088 Osteopenia Diseases 0.000 claims description 2
- 208000002865 Osteopetrosis Diseases 0.000 claims description 2
- 208000008558 Osteophyte Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 210000003689 Pubic Bone Anatomy 0.000 claims description 2
- 208000000924 Right Ventricular Hypertrophy Diseases 0.000 claims description 2
- 208000005688 Salter-Harris Fracture Diseases 0.000 claims description 2
- 201000010103 fibrous dysplasia Diseases 0.000 claims description 2
- 201000010930 hyperostosis Diseases 0.000 claims description 2
- 201000008972 osteitis fibrosa Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 201000009859 osteochondrosis Diseases 0.000 claims description 2
- 230000000750 progressive Effects 0.000 claims description 2
- 201000006409 renal osteodystrophy Diseases 0.000 claims description 2
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 description 70
- -1 HLA-ABC Proteins 0.000 description 50
- 210000002901 Mesenchymal Stem Cells Anatomy 0.000 description 32
- 150000002632 lipids Chemical class 0.000 description 30
- 230000001225 therapeutic Effects 0.000 description 29
- 239000000499 gel Substances 0.000 description 26
- 239000002609 media Substances 0.000 description 25
- 238000004166 bioassay Methods 0.000 description 22
- 230000027455 binding Effects 0.000 description 20
- 239000003446 ligand Substances 0.000 description 17
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 15
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 102100002212 CXCR4 Human genes 0.000 description 13
- 101710003734 CXCR4 Proteins 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 13
- 102100015249 VEGFA Human genes 0.000 description 11
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 11
- 239000000853 adhesive Substances 0.000 description 11
- 230000001070 adhesive Effects 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 10
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- 102100001477 ITGB3 Human genes 0.000 description 9
- 101710006664 ITGB3 Proteins 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 230000003110 anti-inflammatory Effects 0.000 description 9
- 102000004965 antibodies Human genes 0.000 description 9
- 108090001123 antibodies Proteins 0.000 description 9
- 229920001400 block copolymer Polymers 0.000 description 9
- 239000011257 shell material Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 102100008428 CCL2 Human genes 0.000 description 8
- 102100003735 CD44 Human genes 0.000 description 7
- 102100005827 CD63 Human genes 0.000 description 7
- 108010055292 Chemokine CCL2 Proteins 0.000 description 7
- 102100009705 ENG Human genes 0.000 description 7
- 101710004859 ENG Proteins 0.000 description 7
- 102000038595 IGF Type 1 Receptor Human genes 0.000 description 7
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 7
- 102100014231 IGF1 Human genes 0.000 description 7
- 101700074337 IGF1 Proteins 0.000 description 7
- 102100001478 ITGB1 Human genes 0.000 description 7
- 101710006661 ITGB1 Proteins 0.000 description 7
- 210000000265 Leukocytes Anatomy 0.000 description 7
- 102100017063 NT5E Human genes 0.000 description 7
- 101710039712 NT5E Proteins 0.000 description 7
- 102100005499 PTPRC Human genes 0.000 description 7
- 102100008333 THY1 Human genes 0.000 description 7
- 101700026084 THY1 Proteins 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000005012 migration Effects 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 210000004369 Blood Anatomy 0.000 description 6
- 102100016450 CCL7 Human genes 0.000 description 6
- 101700044004 CCL7 Proteins 0.000 description 6
- 101700078950 CD44 Proteins 0.000 description 6
- 102100014691 CXCL12 Human genes 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 101700079540 FAS Proteins 0.000 description 6
- 102100016439 FAS Human genes 0.000 description 6
- 102100019334 ITGA4 Human genes 0.000 description 6
- 102100008588 ITGA5 Human genes 0.000 description 6
- 108090000028 MMP12 Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 102000003729 Neprilysin Human genes 0.000 description 6
- 102000002067 Protein Subunits Human genes 0.000 description 6
- 108010001267 Protein Subunits Proteins 0.000 description 6
- 230000033115 angiogenesis Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004271 bone marrow stromal cells Anatomy 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000001963 growth media Substances 0.000 description 6
- 150000002430 hydrocarbons Chemical class 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000005291 magnetic Effects 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 231100000486 side effect Toxicity 0.000 description 6
- 102100005866 ALCAM Human genes 0.000 description 5
- 102100016549 ANPEP Human genes 0.000 description 5
- 101710028178 ANPEP Proteins 0.000 description 5
- 102100004326 BRAP Human genes 0.000 description 5
- 102100013858 BSG Human genes 0.000 description 5
- 102100016449 CCL5 Human genes 0.000 description 5
- 102100003269 CD151 Human genes 0.000 description 5
- 101700010227 CD151 Proteins 0.000 description 5
- 102100019456 CD276 Human genes 0.000 description 5
- 101700015421 CD276 Proteins 0.000 description 5
- 108060001251 CD34 Proteins 0.000 description 5
- 102100016492 CD34 Human genes 0.000 description 5
- 102100013078 CD47 Human genes 0.000 description 5
- 101700033237 CD47 Proteins 0.000 description 5
- 101710018147 CD58 Proteins 0.000 description 5
- 102100004444 CD58 Human genes 0.000 description 5
- 102100019450 CD81 Human genes 0.000 description 5
- 102100009641 CXCL10 Human genes 0.000 description 5
- 101710032181 CXCL10 Proteins 0.000 description 5
- 102100016662 ERBB2 Human genes 0.000 description 5
- 101700025368 ERBB2 Proteins 0.000 description 5
- 102000003951 Erythropoietin Human genes 0.000 description 5
- 108090000394 Erythropoietin Proteins 0.000 description 5
- 102100015542 FCGR3B Human genes 0.000 description 5
- 101710044657 FCGR3B Proteins 0.000 description 5
- 229950003499 FIBRIN Drugs 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 5
- 108010073385 Fibrin Proteins 0.000 description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 5
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 5
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 5
- 102100008192 IL6ST Human genes 0.000 description 5
- 102100019336 ITGA2 Human genes 0.000 description 5
- 101710006710 ITGA2 Proteins 0.000 description 5
- 102100019335 ITGA3 Human genes 0.000 description 5
- 101710006708 ITGA3 Proteins 0.000 description 5
- 102100012155 ITGA6 Human genes 0.000 description 5
- 101710006669 ITGA6 Proteins 0.000 description 5
- 102100019438 ITGAV Human genes 0.000 description 5
- 101710006691 ITGAV Proteins 0.000 description 5
- 102100012758 LRP1 Human genes 0.000 description 5
- 101700005580 LRP1 Proteins 0.000 description 5
- 102100006043 MCAM Human genes 0.000 description 5
- 101710034704 MCAM Proteins 0.000 description 5
- 102000001756 Notch2 Receptor Human genes 0.000 description 5
- 108010029751 Notch2 Receptor Proteins 0.000 description 5
- 102100004939 PDGFRB Human genes 0.000 description 5
- 101700059076 PTPRC Proteins 0.000 description 5
- 102100016187 PVR Human genes 0.000 description 5
- 102100017643 SLAMF1 Human genes 0.000 description 5
- 101710007458 SLC3A2 Proteins 0.000 description 5
- 102100013834 SLC3A2 Human genes 0.000 description 5
- 101710015409 SLC7A5 Proteins 0.000 description 5
- 102100016327 TEK Human genes 0.000 description 5
- 101710037124 TEK Proteins 0.000 description 5
- 101710030909 TNFRSF13B Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 230000021164 cell adhesion Effects 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 229940105423 erythropoietin Drugs 0.000 description 5
- 235000013902 inosinic acid Nutrition 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 230000014306 paracrine signaling Effects 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 5
- 108010048507 poliovirus receptor Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000004083 survival Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 108060009375 vtc4 Proteins 0.000 description 5
- 102100014001 ABCB1 Human genes 0.000 description 4
- 101700002015 ABCB1 Proteins 0.000 description 4
- 101710033748 ALCAM Proteins 0.000 description 4
- 102100011677 ATP1B3 Human genes 0.000 description 4
- 101710038695 ATP1B3 Proteins 0.000 description 4
- 206010059512 Apoptosis Diseases 0.000 description 4
- 102100015880 BMP6 Human genes 0.000 description 4
- 101710019228 BSG Proteins 0.000 description 4
- 102100001437 BST1 Human genes 0.000 description 4
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 4
- 101700083927 CCR1 Proteins 0.000 description 4
- 102100005860 CCR1 Human genes 0.000 description 4
- 102100018947 CD101 Human genes 0.000 description 4
- 101710024418 CD101 Proteins 0.000 description 4
- 102100003268 CD14 Human genes 0.000 description 4
- 101700027514 CD14 Proteins 0.000 description 4
- 102100009326 CD163 Human genes 0.000 description 4
- 102100005867 CD177 Human genes 0.000 description 4
- 101700024379 CD177 Proteins 0.000 description 4
- 102100005826 CD19 Human genes 0.000 description 4
- 101700087100 CD19 Proteins 0.000 description 4
- 102100010225 CD207 Human genes 0.000 description 4
- 101710026584 CD207 Proteins 0.000 description 4
- 102100000189 CD22 Human genes 0.000 description 4
- 101700056583 CD27 Proteins 0.000 description 4
- 101700044364 CD37 Proteins 0.000 description 4
- 102100016530 CD37 Human genes 0.000 description 4
- 102100003279 CD38 Human genes 0.000 description 4
- 101710040446 CD40 Proteins 0.000 description 4
- 102100013391 CD55 Human genes 0.000 description 4
- 102100003281 CD59 Human genes 0.000 description 4
- 101700052224 CD63 Proteins 0.000 description 4
- 102100005832 CD69 Human genes 0.000 description 4
- 101700080416 CD69 Proteins 0.000 description 4
- 102100005830 CD70 Human genes 0.000 description 4
- 101700017377 CD70 Proteins 0.000 description 4
- 101700062651 CD81 Proteins 0.000 description 4
- 101700087069 CD82 Proteins 0.000 description 4
- 102100008204 CD82 Human genes 0.000 description 4
- 102100011841 CEACAM8 Human genes 0.000 description 4
- 101710043951 CEACAM8 Proteins 0.000 description 4
- 102100009368 CR2 Human genes 0.000 description 4
- 101700020447 CR2 Proteins 0.000 description 4
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 4
- 102100015540 FCGR1A Human genes 0.000 description 4
- 101710003440 FCGR1A Proteins 0.000 description 4
- 102100006279 FZD9 Human genes 0.000 description 4
- 101710023172 FZD9 Proteins 0.000 description 4
- 102100015892 IL12RB1 Human genes 0.000 description 4
- 101710035563 IL12RB1 Proteins 0.000 description 4
- 102100008981 IL18R1 Human genes 0.000 description 4
- 102100006848 IL9R Human genes 0.000 description 4
- 101710006711 ITGA4 Proteins 0.000 description 4
- 101710006709 ITGA5 Proteins 0.000 description 4
- 102100012151 ITGAE Human genes 0.000 description 4
- 101710006585 ITGAE Proteins 0.000 description 4
- 102100001475 ITGB2 Human genes 0.000 description 4
- 102000003814 Interleukin-10 Human genes 0.000 description 4
- 108090000174 Interleukin-10 Proteins 0.000 description 4
- 229940076144 Interleukin-10 Drugs 0.000 description 4
- 102100005918 LAMP1 Human genes 0.000 description 4
- 101700048185 LAMP1 Proteins 0.000 description 4
- 101700039143 LAMP2 Proteins 0.000 description 4
- 102100005969 LAMP2 Human genes 0.000 description 4
- 241000713666 Lentivirus Species 0.000 description 4
- 102100001008 MET Human genes 0.000 description 4
- 102100012644 MIF Human genes 0.000 description 4
- 108060004872 MIF Proteins 0.000 description 4
- 102100004732 MRC1 Human genes 0.000 description 4
- 101700029479 MRC1 Proteins 0.000 description 4
- 102100015258 MYO18A Human genes 0.000 description 4
- 101710042391 MYO18A Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 210000004165 Myocardium Anatomy 0.000 description 4
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 4
- 102100007908 NCR3 Human genes 0.000 description 4
- 101710009588 NCR3 Proteins 0.000 description 4
- 102100019072 NECTIN1 Human genes 0.000 description 4
- 101710005665 NECTIN1 Proteins 0.000 description 4
- 102100008795 NGFR Human genes 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
- 102100007289 PDCD1LG2 Human genes 0.000 description 4
- 101710018346 PDGFRB Proteins 0.000 description 4
- 102000033170 PRNP Human genes 0.000 description 4
- 102100017342 PTPRJ Human genes 0.000 description 4
- 101700020334 PTPRJ Proteins 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 4
- 101710023899 SEMA7A Proteins 0.000 description 4
- 102100017842 SEMA7A Human genes 0.000 description 4
- 102100004480 SIGLEC9 Human genes 0.000 description 4
- 101710045218 SIGLEC9 Proteins 0.000 description 4
- 102000033172 SIRPB1 Human genes 0.000 description 4
- 101710016425 SIRPB1 Proteins 0.000 description 4
- 102100006354 TLR8 Human genes 0.000 description 4
- 102100009744 TNFRSF13B Human genes 0.000 description 4
- 101710040533 TNFRSF8 Proteins 0.000 description 4
- 101710040535 TNFRSF9 Proteins 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 102000009270 Tumour necrosis factor alpha Human genes 0.000 description 4
- 108050000101 Tumour necrosis factor alpha Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007172 antigens Proteins 0.000 description 4
- 102000038129 antigens Human genes 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 125000004429 atoms Chemical group 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002209 hydrophobic Effects 0.000 description 4
- 230000002934 lysing Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 229960001322 trypsin Drugs 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 230000003612 virological Effects 0.000 description 4
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 3
- XSGXRYNZNGUGEJ-LTGZKZEYSA-N 2-(4-benzylpiperazin-1-yl)-N'-[(E)-(6-oxo-5-prop-2-enylcyclohexa-2,4-dien-1-ylidene)methyl]acetohydrazide Chemical compound O=C1C(CC=C)=CC=C\C1=C/NNC(=O)CN1CCN(CC=2C=CC=CC=2)CC1 XSGXRYNZNGUGEJ-LTGZKZEYSA-N 0.000 description 3
- 101700006234 AKT1 Proteins 0.000 description 3
- 102100018910 B3GAT1 Human genes 0.000 description 3
- 101710027071 B3GAT1 Proteins 0.000 description 3
- 101700053225 BST1 Proteins 0.000 description 3
- 102100005862 CCR2 Human genes 0.000 description 3
- 102100008151 CCR7 Human genes 0.000 description 3
- 108010009992 CD163 antigen Proteins 0.000 description 3
- 102100005868 CD180 Human genes 0.000 description 3
- 101700060549 CD180 Proteins 0.000 description 3
- 102100013082 CD1A Human genes 0.000 description 3
- 101700015984 CD1A Proteins 0.000 description 3
- 102100019289 CD2 Human genes 0.000 description 3
- 101700024689 CD2 Proteins 0.000 description 3
- 102100010454 CD200 Human genes 0.000 description 3
- 101710024588 CD200 Proteins 0.000 description 3
- 102100008207 CD209 Human genes 0.000 description 3
- 101700005213 CD209 Proteins 0.000 description 3
- 101700020617 CD22 Proteins 0.000 description 3
- 108060001249 CD24 Proteins 0.000 description 3
- 102100000197 CD24 Human genes 0.000 description 3
- 102100000188 CD244 Human genes 0.000 description 3
- 101700000388 CD244 Proteins 0.000 description 3
- 102100019459 CD27 Human genes 0.000 description 3
- 102100019461 CD28 Human genes 0.000 description 3
- 101700033362 CD28 Proteins 0.000 description 3
- 108010045374 CD36 Antigens Proteins 0.000 description 3
- 101700044948 CD38 Proteins 0.000 description 3
- 102100013137 CD40 Human genes 0.000 description 3
- 102100003729 CD40LG Human genes 0.000 description 3
- 102100013076 CD48 Human genes 0.000 description 3
- 101700012453 CD48 Proteins 0.000 description 3
- 102100005828 CD5 Human genes 0.000 description 3
- 101700066525 CD5 Proteins 0.000 description 3
- 102100019283 CD52 Human genes 0.000 description 3
- 108010065524 CD52 Antigen Proteins 0.000 description 3
- 101710006195 CD55 Proteins 0.000 description 3
- 101700073334 CD59 Proteins 0.000 description 3
- 101700063101 CD7 Proteins 0.000 description 3
- 102100019446 CD72 Human genes 0.000 description 3
- 101700002874 CD72 Proteins 0.000 description 3
- 102100004099 CD74 Human genes 0.000 description 3
- 101710007476 CD74 Proteins 0.000 description 3
- 102100008191 CD8A Human genes 0.000 description 3
- 101700054655 CD8A Proteins 0.000 description 3
- 102100005687 CDH5 Human genes 0.000 description 3
- 102100005695 CDH6 Human genes 0.000 description 3
- 102100011842 CEACAM5 Human genes 0.000 description 3
- 101710026577 CLEC4A Proteins 0.000 description 3
- 102100004330 CLEC4A Human genes 0.000 description 3
- 102100005552 CR1 Human genes 0.000 description 3
- 101700042195 CR1 Proteins 0.000 description 3
- 102100005175 CSF1R Human genes 0.000 description 3
- 102100018759 CSF2RB Human genes 0.000 description 3
- 101710007363 CSF2RB Proteins 0.000 description 3
- 102100006433 CSF3R Human genes 0.000 description 3
- 229920003043 Cellulose fiber Polymers 0.000 description 3
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 3
- 229940106189 Ceramides Drugs 0.000 description 3
- 108010055166 Chemokine CCL5 Proteins 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 102100006837 DDR1 Human genes 0.000 description 3
- 101700058746 DDR1 Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 101710011427 ENTPD1 Proteins 0.000 description 3
- 102100009509 ENTPD1 Human genes 0.000 description 3
- 229940088598 Enzyme Drugs 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102100012318 F3 Human genes 0.000 description 3
- 102100014608 FCER2 Human genes 0.000 description 3
- 101700053597 FCER2 Proteins 0.000 description 3
- 101710044640 FCGR2A Proteins 0.000 description 3
- 102100015543 FCGR2B Human genes 0.000 description 3
- 101710044641 FCGR2B Proteins 0.000 description 3
- 101710044642 FCGR2C Proteins 0.000 description 3
- 102100018000 FGFR2 Human genes 0.000 description 3
- 102100019327 FUT4 Human genes 0.000 description 3
- 101700004786 FUT4 Proteins 0.000 description 3
- 102100004438 GP9 Human genes 0.000 description 3
- 101700055186 GP9 Proteins 0.000 description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 description 3
- 108010058597 HLA-DR Antigens Proteins 0.000 description 3
- 102100003404 HLA-G Human genes 0.000 description 3
- 101710008996 HLA-G Proteins 0.000 description 3
- 102100004115 ICAM1 Human genes 0.000 description 3
- 102100004110 ICAM3 Human genes 0.000 description 3
- 102100014734 ICOS Human genes 0.000 description 3
- 101700078331 ICOS Proteins 0.000 description 3
- 102100008685 IFNGR1 Human genes 0.000 description 3
- 101710030947 IFNGR1 Proteins 0.000 description 3
- 102100008150 IL2RG Human genes 0.000 description 3
- 101700011716 IL2RG Proteins 0.000 description 3
- 101710022768 IL6ST Proteins 0.000 description 3
- 102100012517 ITGB7 Human genes 0.000 description 3
- 101710006575 ITGB7 Proteins 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 102000013462 Interleukin-12 Human genes 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 102100013180 KDR Human genes 0.000 description 3
- 101710030888 KDR Proteins 0.000 description 3
- 102100012810 KIR3DL1 Human genes 0.000 description 3
- 102100016985 KIT Human genes 0.000 description 3
- 101710009391 KIT Proteins 0.000 description 3
- 102100007895 KLRD1 Human genes 0.000 description 3
- 101700071001 KLRD1 Proteins 0.000 description 3
- 101700031346 LY9 Proteins 0.000 description 3
- 102100008256 LY9 Human genes 0.000 description 3
- 101700036258 MECOM Proteins 0.000 description 3
- 102100000165 MS4A1 Human genes 0.000 description 3
- 101710010909 MS4A1 Proteins 0.000 description 3
- 102100003099 MST1R Human genes 0.000 description 3
- 101710029065 MST1R Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102100007907 NCR1 Human genes 0.000 description 3
- 101710009580 NCR1 Proteins 0.000 description 3
- 102100007909 NCR2 Human genes 0.000 description 3
- 101710009579 NCR2 Proteins 0.000 description 3
- 101710011976 PDCD1LG2 Proteins 0.000 description 3
- 102100018916 PLAUR Human genes 0.000 description 3
- 101710008806 PLAUR Proteins 0.000 description 3
- 101710024107 PRNP Proteins 0.000 description 3
- 102100017157 PROM1 Human genes 0.000 description 3
- 101700033975 PROM1 Proteins 0.000 description 3
- 108060006789 PSMG1 Proteins 0.000 description 3
- 102100002906 PSMG1 Human genes 0.000 description 3
- 229940067631 Phospholipids Drugs 0.000 description 3
- 210000002381 Plasma Anatomy 0.000 description 3
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 3
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 3
- 102000035266 SCARB3 Human genes 0.000 description 3
- 101700070405 SDC1 Proteins 0.000 description 3
- 102100010587 SDC1 Human genes 0.000 description 3
- 102100008254 SELL Human genes 0.000 description 3
- 101710038663 SELL Proteins 0.000 description 3
- 102100003519 SELP Human genes 0.000 description 3
- 101700009186 SELP Proteins 0.000 description 3
- 102100001289 SEMA4D Human genes 0.000 description 3
- 102100000940 SETD2 Human genes 0.000 description 3
- 101700071021 SETD2 Proteins 0.000 description 3
- 101710028439 SLAMF1 Proteins 0.000 description 3
- 102100017641 SLAMF6 Human genes 0.000 description 3
- 101710030439 SLAMF6 Proteins 0.000 description 3
- 102100017511 SPN Human genes 0.000 description 3
- 102100012096 TLR2 Human genes 0.000 description 3
- 101700064022 TLR2 Proteins 0.000 description 3
- 101700071772 TLR8 Proteins 0.000 description 3
- 102100009538 TNFRSF8 Human genes 0.000 description 3
- 102100009537 TNFRSF9 Human genes 0.000 description 3
- 102100011846 TNFSF4 Human genes 0.000 description 3
- 101710025695 TNFSF4 Proteins 0.000 description 3
- 102100009581 TPBG Human genes 0.000 description 3
- 101700065141 TPBG Proteins 0.000 description 3
- 229940072056 alginate Drugs 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 150000001783 ceramides Chemical class 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 229960005188 collagen Drugs 0.000 description 3
- 239000000032 diagnostic agent Substances 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002757 inflammatory Effects 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229920000831 ionic polymer Polymers 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000000051 modifying Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- ZAKBPRIDLSBYQQ-VHSXEESVSA-N 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OC[C@@H](O)CO ZAKBPRIDLSBYQQ-VHSXEESVSA-N 0.000 description 2
- HMFKFHLTUCJZJO-UHFFFAOYSA-N 2-{2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy}ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCC(OCCO)C1OCC(OCCO)C1OCCO HMFKFHLTUCJZJO-UHFFFAOYSA-N 0.000 description 2
- 102100009261 ACE Human genes 0.000 description 2
- 102100016908 ACKR1 Human genes 0.000 description 2
- 101710027066 ALB Proteins 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical group C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 2
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 2
- 101700063377 CCL5 Proteins 0.000 description 2
- 101700067628 CCR2 Proteins 0.000 description 2
- 108010017009 CD11b Antigen Proteins 0.000 description 2
- 102000004354 CD11b Antigen Human genes 0.000 description 2
- 102100013953 CD164 Human genes 0.000 description 2
- 108060001246 CD164 Proteins 0.000 description 2
- 102100000166 CD226 Human genes 0.000 description 2
- 101700022117 CD226 Proteins 0.000 description 2
- 102100004490 CD300A Human genes 0.000 description 2
- 101710033667 CD300A Proteins 0.000 description 2
- 101710033670 CD300C Proteins 0.000 description 2
- 102100004485 CD300E Human genes 0.000 description 2
- 101710018048 CD300E Proteins 0.000 description 2
- 102100003280 CD300H Human genes 0.000 description 2
- 101710003707 CD300H Proteins 0.000 description 2
- 101710003804 CD40LG Proteins 0.000 description 2
- 102100019144 CD46 Human genes 0.000 description 2
- 102100019453 CD7 Human genes 0.000 description 2
- 102100008196 CDCP1 Human genes 0.000 description 2
- 101700046287 CDCP1 Proteins 0.000 description 2
- 101710035601 CDH3 Proteins 0.000 description 2
- 102100015554 CDH3 Human genes 0.000 description 2
- 101710035596 CDH5 Proteins 0.000 description 2
- 101710035597 CDH6 Proteins 0.000 description 2
- 102100005193 CSF2RA Human genes 0.000 description 2
- 101710008988 CSF2RA Proteins 0.000 description 2
- 101700017008 CSF3R Proteins 0.000 description 2
- 102100005310 CTLA4 Human genes 0.000 description 2
- 101700054183 CTLA4 Proteins 0.000 description 2
- 101710043128 CXCL12 Proteins 0.000 description 2
- 102000000905 Cadherins Human genes 0.000 description 2
- 108050007957 Cadherins Proteins 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 102100006840 DDR2 Human genes 0.000 description 2
- 101700005454 DDR2 Proteins 0.000 description 2
- 102100012353 DPP4 Human genes 0.000 description 2
- 102100017419 ENPEP Human genes 0.000 description 2
- 101700054532 ENPP3 Proteins 0.000 description 2
- 102100016622 ENPP3 Human genes 0.000 description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000713730 Equine infectious anemia virus Species 0.000 description 2
- 210000003743 Erythrocytes Anatomy 0.000 description 2
- 102100012510 F11R Human genes 0.000 description 2
- 101700029199 F3 Proteins 0.000 description 2
- 101710008102 FASN Proteins 0.000 description 2
- 102100014612 FCAMR Human genes 0.000 description 2
- 101700025784 FCAMR Proteins 0.000 description 2
- 102000018233 Fibroblast growth factor family Human genes 0.000 description 2
- 108050007372 Fibroblast growth factor family Proteins 0.000 description 2
- 101710008404 GAPDH Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229960002743 Glutamine Drugs 0.000 description 2
- 229960004956 Glycerylphosphorylcholine Drugs 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 229960002897 Heparin Drugs 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229940099552 Hyaluronan Drugs 0.000 description 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N Hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
- 101700014306 ICAM3 Proteins 0.000 description 2
- 102100015897 IL10RA Human genes 0.000 description 2
- 101710032882 IL10RA Proteins 0.000 description 2
- 102100004549 IL13RA2 Human genes 0.000 description 2
- 101710034342 IL13RA2 Proteins 0.000 description 2
- 102100004545 IL17RA Human genes 0.000 description 2
- 101710035970 IL17RA Proteins 0.000 description 2
- 101710006739 IL18R1 Proteins 0.000 description 2
- 102100004838 IL1R2 Human genes 0.000 description 2
- 101700043314 IL1R2 Proteins 0.000 description 2
- 102100005025 IL21R Human genes 0.000 description 2
- 101700084682 IL21R Proteins 0.000 description 2
- 102100006815 IL2RA Human genes 0.000 description 2
- 101700082799 IL2RA Proteins 0.000 description 2
- 102100006816 IL2RB Human genes 0.000 description 2
- 101700021467 IL2RB Proteins 0.000 description 2
- 102100018760 IL3RA Human genes 0.000 description 2
- 101700029869 IL3RA Proteins 0.000 description 2
- 102100004993 IL5RA Human genes 0.000 description 2
- 101700082749 IL5RA Proteins 0.000 description 2
- 102100014194 IL7R Human genes 0.000 description 2
- 101710025228 IL7R Proteins 0.000 description 2
- 101700053101 IL9R Proteins 0.000 description 2
- 102100019333 ITGA1 Human genes 0.000 description 2
- 101710006663 ITGB2 Proteins 0.000 description 2
- 210000000987 Immune System Anatomy 0.000 description 2
- 102000018358 Immunoglobulins Human genes 0.000 description 2
- 108060003951 Immunoglobulins Proteins 0.000 description 2
- 210000004969 Inflammatory Cells Anatomy 0.000 description 2
- 108010041361 Integrin alpha2 Proteins 0.000 description 2
- 102000000507 Integrin alpha2 Human genes 0.000 description 2
- 108010041357 Integrin alpha3 Proteins 0.000 description 2
- 102000000510 Integrin alpha3 Human genes 0.000 description 2
- 108010041100 Integrin alpha6 Proteins 0.000 description 2
- 102000000426 Integrin alpha6 Human genes 0.000 description 2
- 108010022222 Integrin beta1 Proteins 0.000 description 2
- 102000012355 Integrin beta1 Human genes 0.000 description 2
- 108010022238 Integrin beta4 Proteins 0.000 description 2
- 102000012334 Integrin beta4 Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102000004125 Interleukin-1alpha Human genes 0.000 description 2
- 108010082786 Interleukin-1alpha Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102100012511 JAM2 Human genes 0.000 description 2
- 102100012792 KIR2DL1 Human genes 0.000 description 2
- 101710038974 KIR3DL1 Proteins 0.000 description 2
- 101700014816 KLRB1 Proteins 0.000 description 2
- 102100007899 KLRB1 Human genes 0.000 description 2
- 102100017339 KLRC1 Human genes 0.000 description 2
- 101710036388 KLRC1 Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 102100004400 L1CAM Human genes 0.000 description 2
- 102100017213 LAG3 Human genes 0.000 description 2
- 108060004270 LAG3 Proteins 0.000 description 2
- 102100017662 LEPR Human genes 0.000 description 2
- 102100011647 LIFR Human genes 0.000 description 2
- 102100004887 LILRA2 Human genes 0.000 description 2
- 101710002790 LILRA2 Proteins 0.000 description 2
- 102100004901 LILRB1 Human genes 0.000 description 2
- 102100010013 LILRB2 Human genes 0.000 description 2
- 101710002780 LILRB2 Proteins 0.000 description 2
- 102100010012 LILRB3 Human genes 0.000 description 2
- 101710002779 LILRB3 Proteins 0.000 description 2
- 102100011002 LY75 Human genes 0.000 description 2
- 101700062805 LY75 Proteins 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N Lauric acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 206010024324 Leukaemias Diseases 0.000 description 2
- 108010013709 Leukocyte Common Antigens Proteins 0.000 description 2
- 108010009489 Lysosomal-Associated Membrane Protein 3 Proteins 0.000 description 2
- 102100000250 MPL Human genes 0.000 description 2
- 102100004660 MSR1 Human genes 0.000 description 2
- 101700001066 MSR1 Proteins 0.000 description 2
- 102100006037 MUC1 Human genes 0.000 description 2
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 2
- 235000021360 Myristic acid Nutrition 0.000 description 2
- LKQLRGMMMAHREN-YJFXYUILSA-N N-stearoylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC LKQLRGMMMAHREN-YJFXYUILSA-N 0.000 description 2
- 102100002692 NFKB1 Human genes 0.000 description 2
- 101700086102 NFKB1 Proteins 0.000 description 2
- 101710038602 NGFR Proteins 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 108010054395 P-selectin ligand protein Proteins 0.000 description 2
- 102100007816 PDGFC Human genes 0.000 description 2
- 102100017565 PDGFD Human genes 0.000 description 2
- 101700025642 PDGFD Proteins 0.000 description 2
- 102100004940 PDGFRA Human genes 0.000 description 2
- 101710018349 PDGFRA Proteins 0.000 description 2
- 102100002428 PML Human genes 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N Palmitic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- UNJJBGNPUUVVFQ-ZJUUUORDSA-N Phosphatidylserine Chemical compound CCCC(=O)O[C@H](COC(=O)CC)COP(O)(=O)OC[C@H](N)C(O)=O UNJJBGNPUUVVFQ-ZJUUUORDSA-N 0.000 description 2
- 229920002518 Polyallylamine hydrochloride Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010036807 Progressive multifocal leukoencephalopathy Diseases 0.000 description 2
- 210000003324 RBC Anatomy 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100014586 SELPLG Human genes 0.000 description 2
- 101710023772 SEMA4D Proteins 0.000 description 2
- 102100018868 SIGLEC1 Human genes 0.000 description 2
- 102100004491 SIGLEC5 Human genes 0.000 description 2
- 101710045184 SIGLEC5 Proteins 0.000 description 2
- 102100016152 SIRPG Human genes 0.000 description 2
- 101700021698 SIRPG Proteins 0.000 description 2
- 101700030874 SOX9 Proteins 0.000 description 2
- 101710018229 SPN Proteins 0.000 description 2
- 210000002966 Serum Anatomy 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 102100006353 TLR6 Human genes 0.000 description 2
- 101700030074 TLR6 Proteins 0.000 description 2
- 101710030862 TNFRSF13C Proteins 0.000 description 2
- 101710038526 TNFRSF1A Proteins 0.000 description 2
- 102100003095 TNFRSF1A Human genes 0.000 description 2
- 101710038524 TNFRSF1B Proteins 0.000 description 2
- 102100003105 TNFRSF1B Human genes 0.000 description 2
- 101710008042 TNFRSF21 Proteins 0.000 description 2
- 102100002198 TNFSF10 Human genes 0.000 description 2
- 101710022353 TNFSF10 Proteins 0.000 description 2
- 102100002199 TNFSF11 Human genes 0.000 description 2
- 102100002237 TNFSF13 Human genes 0.000 description 2
- 101710022362 TNFSF13 Proteins 0.000 description 2
- 102100002238 TNFSF14 Human genes 0.000 description 2
- 102100003083 TNFSF8 Human genes 0.000 description 2
- 101710025687 TNFSF8 Proteins 0.000 description 2
- 101710041050 TSPAN7 Proteins 0.000 description 2
- 102100016885 TSPAN7 Human genes 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 101710010287 YWHAZ Proteins 0.000 description 2
- IYFATESGLOUGBX-CBOZIWPYSA-N [2-[(2R,3S,4R)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@@H](O)[C@@H]1O IYFATESGLOUGBX-CBOZIWPYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 231100000494 adverse effect Toxicity 0.000 description 2
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 description 2
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 description 2
- 230000002491 angiogenic Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000002449 bone cell Anatomy 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 210000003321 cartilage cell Anatomy 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 238000007374 clinical diagnostic method Methods 0.000 description 2
- 239000003636 conditioned culture media Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 230000029578 entry into host Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 108091004535 flt3 ligand protein Proteins 0.000 description 2
- 238000003260 fluorescence intensity Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000003278 mimic Effects 0.000 description 2
- 230000001264 neutralization Effects 0.000 description 2
- 230000003204 osmotic Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 150000002926 oxygen Chemical class 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 108010017992 platelet-derived growth factor C Proteins 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001992 poloxamer 407 Polymers 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 230000001737 promoting Effects 0.000 description 2
- DDBRXOJCLVGHLX-UHFFFAOYSA-O propane;trimethylazanium Chemical compound CCC.C[NH+](C)C DDBRXOJCLVGHLX-UHFFFAOYSA-O 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- XVTUQDWPJJBEHJ-KZCWQMDCSA-N tetrastearoyl cardiolipin Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)CO[P@@](O)(=O)OCC(O)CO[P@](O)(=O)OC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC XVTUQDWPJJBEHJ-KZCWQMDCSA-N 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OPCHFPHZPIURNA-MFERNQICSA-N (2S)-2,5-bis(3-aminopropylamino)-N-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2S,4S,5R,6R)-5-acetamido-2-{[(2S,3R,4S,5S,6R)-2-{[(2R,3R,4R,5R)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1R,2R)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 1
- ODBNHBMRTCHJEH-RYXDBFSOSA-N (2S,4S,5R,6R)-5-acetamido-6-[(1S,2R)-2-[(2S,4S,5R,6R)-5-acetamido-6-[(1R,2R)-3-acetyloxy-1,2-dihydroxypropyl]-2-carboxy-4-hydroxyoxan-2-yl]oxy-1,3-dihydroxypropyl]-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-6-[(E,2S,3R)-2-acetamido-3-hydroxyoctadec-4-enoxy]- Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(C)=O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@@H](CO)O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)COC(C)=O)C(O)=O)C(O)=O)[C@@H](O)[C@@H](CO)O1 ODBNHBMRTCHJEH-RYXDBFSOSA-N 0.000 description 1
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N 1-Tetradecanol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 1
- 108010020567 12E7 Antigen Proteins 0.000 description 1
- 102000008482 12E7 Antigen Human genes 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- 101710025088 66 Proteins 0.000 description 1
- 102100012009 A4GALT Human genes 0.000 description 1
- 101700040074 ABCG2 Proteins 0.000 description 1
- 102100002706 ABCG2 Human genes 0.000 description 1
- 108010005465 AC133 Antigen Proteins 0.000 description 1
- 102000005908 AC133 Antigen Human genes 0.000 description 1
- 101710005032 ADGRE5 Proteins 0.000 description 1
- 102100020523 ADGRE5 Human genes 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 101700029306 ANG1 Proteins 0.000 description 1
- 101700039383 AOX1 Proteins 0.000 description 1
- 241000432074 Adeno-associated virus Species 0.000 description 1
- 210000004504 Adult Stem Cells Anatomy 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 206010064930 Age-related macular degeneration Diseases 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102100014323 BMPR1A Human genes 0.000 description 1
- 101710024842 BMPR1A Proteins 0.000 description 1
- 102100007700 BST2 Human genes 0.000 description 1
- 102100009333 BTLA Human genes 0.000 description 1
- 101700047069 BTLA Proteins 0.000 description 1
- 102100015493 BTN3A1 Human genes 0.000 description 1
- 101710012713 BTN3A1 Proteins 0.000 description 1
- 108060003435 Beta Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 102100017562 C5AR1 Human genes 0.000 description 1
- 101700049499 C5AR1 Proteins 0.000 description 1
- 101700070842 CCR3 Proteins 0.000 description 1
- 102100005861 CCR3 Human genes 0.000 description 1
- 101700024589 CCR4 Proteins 0.000 description 1
- 102100012080 CCR5 Human genes 0.000 description 1
- 101700043583 CCR5 Proteins 0.000 description 1
- 101700019063 CCR6 Proteins 0.000 description 1
- 102100008133 CCR6 Human genes 0.000 description 1
- 101700029727 CCR8 Proteins 0.000 description 1
- 102100008148 CCR8 Human genes 0.000 description 1
- 101700076302 CCR9 Proteins 0.000 description 1
- 108010049990 CD13 Antigens Proteins 0.000 description 1
- 101710039069 CD160 Proteins 0.000 description 1
- 101700070268 CD1D Proteins 0.000 description 1
- 102100013079 CD1D Human genes 0.000 description 1
- 102100007290 CD274 Human genes 0.000 description 1
- 102100016493 CD33 Human genes 0.000 description 1
- 102100016494 CD36 Human genes 0.000 description 1
- 101710027020 CD46 Proteins 0.000 description 1
- 101700029492 CD53 Proteins 0.000 description 1
- 102100019284 CD53 Human genes 0.000 description 1
- 108010084313 CD58 Antigens Proteins 0.000 description 1
- 102100019451 CD80 Human genes 0.000 description 1
- 101700080477 CD80 Proteins 0.000 description 1
- 102100008186 CD83 Human genes 0.000 description 1
- 101700013105 CD83 Proteins 0.000 description 1
- 102100017642 CD84 Human genes 0.000 description 1
- 101710028436 CD84 Proteins 0.000 description 1
- 102100007824 CD93 Human genes 0.000 description 1
- 101710028675 CD93 Proteins 0.000 description 1
- 102100014435 CD96 Human genes 0.000 description 1
- 101710026045 CD96 Proteins 0.000 description 1
- 102100004728 CDH1 Human genes 0.000 description 1
- 101700016900 CDH1 Proteins 0.000 description 1
- 102100015399 CDH11 Human genes 0.000 description 1
- 101710005912 CDH2 Proteins 0.000 description 1
- 102100014481 CDH2 Human genes 0.000 description 1
- 101700024634 CDK16 Proteins 0.000 description 1
- 102100011836 CEACAM3 Human genes 0.000 description 1
- 101710043954 CEACAM3 Proteins 0.000 description 1
- 102100011839 CEACAM6 Human genes 0.000 description 1
- 101710043949 CEACAM6 Proteins 0.000 description 1
- 101710026546 CLEC10A Proteins 0.000 description 1
- 102100003426 CLEC10A Human genes 0.000 description 1
- 102100004346 CLEC4C Human genes 0.000 description 1
- 101710026582 CLEC4C Proteins 0.000 description 1
- 102100010226 CLEC4M Human genes 0.000 description 1
- 101710026585 CLEC4M Proteins 0.000 description 1
- 102100011418 CRTAM Human genes 0.000 description 1
- 101700054874 CRTAM Proteins 0.000 description 1
- 101700063802 CSF1R Proteins 0.000 description 1
- 102000019388 CXC chemokine Human genes 0.000 description 1
- 108050006947 CXC chemokine Proteins 0.000 description 1
- 101700072041 CXCL1 Proteins 0.000 description 1
- 102100018698 CXCL1 Human genes 0.000 description 1
- 102100009664 CXCL2 Human genes 0.000 description 1
- 101700075102 CXCL2 Proteins 0.000 description 1
- 101700079756 CXCR3 Proteins 0.000 description 1
- 102100002226 CXCR3 Human genes 0.000 description 1
- 101710025651 CXCR5 Proteins 0.000 description 1
- 102100002072 CXCR5 Human genes 0.000 description 1
- 101700060333 CXCR6 Proteins 0.000 description 1
- 102100002068 CXCR6 Human genes 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- 241000189662 Calla Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108010088013 Carbonic Anhydrase IX Proteins 0.000 description 1
- 102000008646 Carbonic Anhydrase IX Human genes 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 108010014419 Chemokine CXCL1 Proteins 0.000 description 1
- 102000016950 Chemokine CXCL1 Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229940107161 Cholesterol Drugs 0.000 description 1
- 210000001612 Chondrocytes Anatomy 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N Chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- 210000003748 Coronary Sinus Anatomy 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108010006197 Cytokine Receptor gp130 Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101700028524 DID Proteins 0.000 description 1
- 101700062901 DPP Proteins 0.000 description 1
- 101700086219 DVA-1 Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108030002334 EC 2.4.1.228 Proteins 0.000 description 1
- 102100016655 ERN1 Human genes 0.000 description 1
- 101700036757 ERN1 Proteins 0.000 description 1
- 101700014948 ERN2 Proteins 0.000 description 1
- 210000001671 Embryonic Stem Cells Anatomy 0.000 description 1
- 108010009900 Endothelial Protein C Receptor Proteins 0.000 description 1
- 102000009839 Endothelial Protein C Receptor Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N Endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 210000003989 Endothelium, Vascular Anatomy 0.000 description 1
- DNVPQKQSNYMLRS-APGDWVJJSA-N Ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-APGDWVJJSA-N 0.000 description 1
- DNVPQKQSNYMLRS-LNHMRCHQSA-N Ergosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3C([C@H]4[C@@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)=CC=2)CC1 DNVPQKQSNYMLRS-LNHMRCHQSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102100014610 FCAR Human genes 0.000 description 1
- 101700041688 FCAR Proteins 0.000 description 1
- 101710044656 FCGR3A Proteins 0.000 description 1
- 102100020191 FGFR3 Human genes 0.000 description 1
- 102100020189 FGFR4 Human genes 0.000 description 1
- 101700075612 FGFR4 Proteins 0.000 description 1
- 102100004573 FLT3 Human genes 0.000 description 1
- 101710009074 FLT3 Proteins 0.000 description 1
- 241000272184 Falconiformes Species 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 241000713800 Feline immunodeficiency virus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010022355 Fibroins Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102100003517 GP1BA Human genes 0.000 description 1
- 101700034668 GP1BA Proteins 0.000 description 1
- 102100018914 GYPA Human genes 0.000 description 1
- 101710042158 GYPA Proteins 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 102100003042 HIF1A Human genes 0.000 description 1
- 102000026088 HLA-A2 Antigen Human genes 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 239000012593 Hanks’ Balanced Salt Solution Substances 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006822 Human Serum Albumin Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 description 1
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 description 1
- 102100004114 ICAM2 Human genes 0.000 description 1
- 101700035976 ICAM2 Proteins 0.000 description 1
- 102100014733 ICOSLG Human genes 0.000 description 1
- 101710039212 ICOSLG Proteins 0.000 description 1
- 102100014263 IGF1R Human genes 0.000 description 1
- 101700025802 IGF1R Proteins 0.000 description 1
- 102100013307 IGF2R Human genes 0.000 description 1
- 101710032496 IGF2R Proteins 0.000 description 1
- 101710035264 IL15RA Proteins 0.000 description 1
- 102100004550 IL15RA Human genes 0.000 description 1
- 102100009237 IL18RAP Human genes 0.000 description 1
- 102100015968 IL4R Human genes 0.000 description 1
- 101710008343 IL4R Proteins 0.000 description 1
- 102100013321 INSR Human genes 0.000 description 1
- 101700085586 IRE1A Proteins 0.000 description 1
- 101700019719 IRE1B Proteins 0.000 description 1
- 102100019442 ITGAL Human genes 0.000 description 1
- 101710006573 ITGAL Proteins 0.000 description 1
- 102100019441 ITGAM Human genes 0.000 description 1
- 101710006572 ITGAM Proteins 0.000 description 1
- 102100019437 ITGAX Human genes 0.000 description 1
- 101710006689 ITGAX Proteins 0.000 description 1
- 102100001473 ITGB4 Human genes 0.000 description 1
- 101710006665 ITGB4 Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010041341 Integrin alpha1 Proteins 0.000 description 1
- 108010041012 Integrin alpha4 Proteins 0.000 description 1
- 108010041014 Integrin alpha5 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108010028784 Interleukin-18 Receptor alpha Subunit Proteins 0.000 description 1
- 108010018976 Interleukin-8A Receptors Proteins 0.000 description 1
- 108010038414 Interleukin-9 Receptors Proteins 0.000 description 1
- 229940047122 Interleukins Drugs 0.000 description 1
- 102100006542 JAG1 Human genes 0.000 description 1
- 101700058295 JAG1 Proteins 0.000 description 1
- 101700020596 JAM2 Proteins 0.000 description 1
- 210000001503 Joints Anatomy 0.000 description 1
- 108010040082 Junctional Adhesion Molecule A Proteins 0.000 description 1
- 101710037281 KIR2DL1 Proteins 0.000 description 1
- 108010023842 KIR2DL1 Receptors Proteins 0.000 description 1
- 102100012789 KIR2DL2 Human genes 0.000 description 1
- 108010023852 KIR2DL2 Receptors Proteins 0.000 description 1
- 102100012790 KIR2DL3 Human genes 0.000 description 1
- 108010023867 KIR2DL3 Receptors Proteins 0.000 description 1
- 102100012806 KIR2DL4 Human genes 0.000 description 1
- 108010023844 KIR2DL4 Receptors Proteins 0.000 description 1
- 101710037317 KIR2DL5A Proteins 0.000 description 1
- 101710037120 KIR2DS4 Proteins 0.000 description 1
- 102100012798 KIR3DS1 Human genes 0.000 description 1
- 101710038947 KIR3DS1 Proteins 0.000 description 1
- 102100012225 KLRC2 Human genes 0.000 description 1
- 101710036391 KLRC2 Proteins 0.000 description 1
- 102100012223 KLRK1 Human genes 0.000 description 1
- 101710036390 KLRK1 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 102100016650 LAIR1 Human genes 0.000 description 1
- 101700010670 LAIR1 Proteins 0.000 description 1
- 102100005968 LAMP3 Human genes 0.000 description 1
- 101700017305 LAMP3 Proteins 0.000 description 1
- 101700021119 LEUC Proteins 0.000 description 1
- 102100004889 LILRA4 Human genes 0.000 description 1
- 101710002797 LILRA4 Proteins 0.000 description 1
- 101710002781 LILRB1 Proteins 0.000 description 1
- 101710040442 LTBR Proteins 0.000 description 1
- 229940058690 Lanosterol Drugs 0.000 description 1
- CAHGCLMLTWQZNJ-DFHJLLNLSA-N Lanosterol Natural products C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@]21C CAHGCLMLTWQZNJ-DFHJLLNLSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 108010017736 Leukocyte Immunoglobulin-like Receptor B1 Proteins 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 102000011965 Lipoprotein Receptors Human genes 0.000 description 1
- 108010061306 Lipoprotein Receptors Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710007526 MAP3K14 Proteins 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 208000002780 Macular Degeneration Diseases 0.000 description 1
- 210000001616 Monocytes Anatomy 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- VODZWWMEJITOND-OWWNRXNESA-N N-Stearoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCC(=O)NC(CO)C(O)\C=C\CCCCCCCCCCCCC VODZWWMEJITOND-OWWNRXNESA-N 0.000 description 1
- SKVWSNOLUIYQFD-YQUYJWMZSA-N N-[(2S,3R,4R,5R,6R)-2-[(2R,3R,4S,5S,6R)-2-[(2R,3R,4R,5R,6S)-6-[(2R,3S,4R,5R,6R)-6-[(E,2S,3R)-2-formamido-3-hydroxyoctadec-4-enoxy]-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxa Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC=O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O4)O)[C@@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 SKVWSNOLUIYQFD-YQUYJWMZSA-N 0.000 description 1
- 102000008789 N-cadherin Human genes 0.000 description 1
- 108050000637 N-cadherin Proteins 0.000 description 1
- 102100007544 NCAM1 Human genes 0.000 description 1
- 101700077124 NCAM1 Proteins 0.000 description 1
- 102100000486 NECTIN2 Human genes 0.000 description 1
- 101710005673 NECTIN2 Proteins 0.000 description 1
- 102000000835 NK Cell Lectin-Like Receptor Subfamily B Human genes 0.000 description 1
- 108010001882 NK Cell Lectin-Like Receptor Subfamily B Proteins 0.000 description 1
- 102000015223 NK Cell Lectin-Like Receptors Human genes 0.000 description 1
- 108010039435 NK Cell Lectin-Like Receptors Proteins 0.000 description 1
- 102100016565 NOX1 Human genes 0.000 description 1
- 101700076118 NOX1 Proteins 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 description 1
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 description 1
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 1
- 102000002111 Neuropilin Human genes 0.000 description 1
- 108050009450 Neuropilin Proteins 0.000 description 1
- 108010064527 OSM-LIF Receptors Proteins 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N Octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N Oleyl alcohol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000366596 Osiris Species 0.000 description 1
- 208000000035 Osteochondroma Diseases 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 102100019764 PDCD1 Human genes 0.000 description 1
- 108091007929 PDGF receptors Proteins 0.000 description 1
- 101700039373 PDPN Proteins 0.000 description 1
- 102100018806 PDPN Human genes 0.000 description 1
- 101710027269 PECAM1 Proteins 0.000 description 1
- 108060006601 PRM1 Proteins 0.000 description 1
- 102100010921 PROCR Human genes 0.000 description 1
- 102100007288 PTGDR2 Human genes 0.000 description 1
- 101710013017 PTGDR2 Proteins 0.000 description 1
- 101710033203 PTPN6 Proteins 0.000 description 1
- 102100003367 PTPN6 Human genes 0.000 description 1
- 101700044505 PUB33 Proteins 0.000 description 1
- 101700045570 PUB34 Proteins 0.000 description 1
- 101700046887 PUB35 Proteins 0.000 description 1
- 101700066160 PUB51 Proteins 0.000 description 1
- 101700067511 PUB52 Proteins 0.000 description 1
- 101700068819 PUB53 Proteins 0.000 description 1
- 101700086326 PUB70 Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
- 229950008882 Polysorbate Drugs 0.000 description 1
- 102000030002 Prion Proteins Human genes 0.000 description 1
- 108091000054 Prion Proteins Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 101710019485 RARS2 Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102100003520 SELE Human genes 0.000 description 1
- 101710044288 SIGLEC12 Proteins 0.000 description 1
- 102100004479 SIGLEC7 Human genes 0.000 description 1
- 101710045220 SIGLEC7 Proteins 0.000 description 1
- 102100004476 SIRPA Human genes 0.000 description 1
- 101710024246 SIRPA Proteins 0.000 description 1
- 102100017640 SLAMF7 Human genes 0.000 description 1
- 101710030435 SLAMF7 Proteins 0.000 description 1
- 101710036794 SLC44A1 Proteins 0.000 description 1
- 102100014611 SLC44A1 Human genes 0.000 description 1
- 108060007796 SPATA2 Proteins 0.000 description 1
- 108010015534 SS-A antibodies Proteins 0.000 description 1
- 101710039861 ST6GAL1 Proteins 0.000 description 1
- 102100007241 ST6GAL1 Human genes 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 108010029176 Sialic Acid Binding Ig-like Lectin 1 Proteins 0.000 description 1
- 108010029157 Sialic Acid Binding Ig-like Lectin 2 Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 229940087562 Sodium Acetate Trihydrate Drugs 0.000 description 1
- UPMFZISCCZSDND-JJKGCWMISA-M Sodium gluconate Chemical compound [Na+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O UPMFZISCCZSDND-JJKGCWMISA-M 0.000 description 1
- 229940005574 Sodium gluconate Drugs 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229940032091 Stigmasterol Drugs 0.000 description 1
- HCXVJBMSMIARIN-MFBJGPNFSA-N Stigmasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@@H](/C=C/[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 HCXVJBMSMIARIN-MFBJGPNFSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- SFZCNBIFKDRMGX-UHFFFAOYSA-N Sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 description 1
- 102000003705 Syndecan-1 Human genes 0.000 description 1
- 108090000058 Syndecan-1 Proteins 0.000 description 1
- 101700007481 TET7 Proteins 0.000 description 1
- 102100008904 TFRC Human genes 0.000 description 1
- 101710036041 TFRC Proteins 0.000 description 1
- 102100008471 THBD Human genes 0.000 description 1
- 102100002617 TLR1 Human genes 0.000 description 1
- 101700068316 TLR1 Proteins 0.000 description 1
- 102100011746 TLR10 Human genes 0.000 description 1
- 101700053398 TLR10 Proteins 0.000 description 1
- 102100012087 TLR4 Human genes 0.000 description 1
- 102100009534 TNF Human genes 0.000 description 1
- 108091007014 TNFRSF10A Proteins 0.000 description 1
- 101710030970 TNFRSF10B Proteins 0.000 description 1
- 108091007015 TNFRSF10C Proteins 0.000 description 1
- 101710030968 TNFRSF10D Proteins 0.000 description 1
- 102100009743 TNFRSF13C Human genes 0.000 description 1
- 102100008790 TNFRSF14 Human genes 0.000 description 1
- 101710038601 TNFRSF14 Proteins 0.000 description 1
- 101710038604 TNFRSF17 Proteins 0.000 description 1
- 101710038603 TNFRSF18 Proteins 0.000 description 1
- 102100013135 TNFRSF4 Human genes 0.000 description 1
- 101710040448 TNFRSF4 Proteins 0.000 description 1
- 101710022358 TNFSF11 Proteins 0.000 description 1
- 102100009493 TNFSF13B Human genes 0.000 description 1
- 101710004627 TNFSF13B Proteins 0.000 description 1
- 101710022360 TNFSF14 Proteins 0.000 description 1
- 102100008479 TREM1 Human genes 0.000 description 1
- 101700003545 TXLR1 Proteins 0.000 description 1
- 210000001138 Tears Anatomy 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N Tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 108010070774 Thrombopoietin Receptors Proteins 0.000 description 1
- 101700052365 Tlr11 Proteins 0.000 description 1
- 101700081057 Tlr12 Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000002993 Trophoblasts Anatomy 0.000 description 1
- 108010065158 Tumor Necrosis Factor Ligand Superfamily Member 14 Proteins 0.000 description 1
- 102100019577 VCAM1 Human genes 0.000 description 1
- 101700058634 VCAM1 Proteins 0.000 description 1
- 101700072533 VM2 Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2S,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 description 1
- IYFATESGLOUGBX-NDUCAMMLSA-N [2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-NDUCAMMLSA-N 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 230000003044 adaptive Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002293 adipogenic Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000002424 anti-apoptotic Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 1
- 230000001640 apoptogenic Effects 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 230000008267 autocrine signaling Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 201000011143 bone giant cell tumor Diseases 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000006143 cell culture media Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001889 chemoattractant Effects 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000003399 chemotactic Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt Chemical group [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 230000002281 colonystimulating Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000009273 endometriosis Diseases 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000003394 haemopoietic Effects 0.000 description 1
- KYYWBEYKBLQSFW-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O KYYWBEYKBLQSFW-UHFFFAOYSA-N 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 230000003054 hormonal Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000001146 hypoxic Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000001976 improved Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 101700017034 iphP Proteins 0.000 description 1
- 101700052395 ire-1 Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 101710005092 jam2a Proteins 0.000 description 1
- 230000000366 juvenile Effects 0.000 description 1
- 101710030893 kdrl Proteins 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000002147 killing Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- CAHGCLMLTWQZNJ-BQNIITSRSA-N lanosterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@@H](CCC=C(C)C)C)CC[C@]21C CAHGCLMLTWQZNJ-BQNIITSRSA-N 0.000 description 1
- 238000000707 layer-by-layer assembly Methods 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- 230000004301 light adaptation Effects 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 210000001704 mesoblast Anatomy 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000001617 migratory Effects 0.000 description 1
- 239000006956 minimum essential medium Substances 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 229960000060 monoclonal antibodies Drugs 0.000 description 1
- 201000009251 multiple myeloma Diseases 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 230000001272 neurogenic Effects 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Chemical group [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000000790 osteoblast Effects 0.000 description 1
- 230000002188 osteogenic Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 101710031992 pRL90232 Proteins 0.000 description 1
- 230000005298 paramagnetic Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 101710035540 plaa2 Proteins 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 108010079133 potassium transporting ATPase Proteins 0.000 description 1
- OFPTZWGZSRJCOT-MSPNRCMCSA-M potassium;2-[(1S,2S,3R,4S,5S,6R)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;(2S,5R,6R)-3,3-d Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O OFPTZWGZSRJCOT-MSPNRCMCSA-M 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000000770 pro-inflamatory Effects 0.000 description 1
- 230000001686 pro-survival Effects 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000036678 protein binding Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 125000005373 siloxane group Chemical group [SiH2](O*)* 0.000 description 1
- 238000003530 single readout Methods 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- AYRVGWHSXIMRAB-UHFFFAOYSA-M sodium acetate trihydrate Chemical compound O.O.O.[Na+].CC([O-])=O AYRVGWHSXIMRAB-UHFFFAOYSA-M 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 108010006325 sodium-translocating ATPase Proteins 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 101700021125 sptP Proteins 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 230000003319 supportive Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 230000002195 synergetic Effects 0.000 description 1
- 230000001732 thrombotic Effects 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 1
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000000982 vasogenic Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 200000000019 wound Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N β-Sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/115—Platelets, megakaryocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
- C12N5/0633—Cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
Abstract
The invention relates to immuno-modulatory progenitor (IMP) cells and their use in therapy. A population of IMP cells derived from bone marrow mononuclear cells that express on their surfaces detectable levels of MIC A/B, CD304, CD178, CD289, CD363, CD99,CD181,EFG-R, CXCR2 and secrete IL-6 and IL-8. Wherein the cells are produced using by (i) culturing mononuclear cells (MCs) for from 15 to 25 days in a medium comprising platelet lysate, at less than 20% oxygen (O2) and under conditions which allow the MCs to adhere to induce the MCs to differentiate into IMP cells and (ii) harvesting and culturing those IMP cells which have an expression pattern as defined in claim 1 and thereby producing a population according to claim 1, wherein the platelet lysate is produced by subjecting a population of human platelets to four freeze-thaw cycles, wherein the freeze portion of each cycle is carried out in liquid nitrogen. Wherein the cells are produced using by (i) culturing mononuclear cells (MCs) for from 15 to 25 days in a medium comprising platelet lysate, at less than 20% oxygen (O2) and under conditions which allow the MCs to adhere to induce the MCs to differentiate into IMP cells and (ii) harvesting and culturing those IMP cells which have an expression pattern as defined in claim 1 and thereby producing a population according to claim 1, wherein the platelet lysate is produced by subjecting a population of human platelets to four freeze-thaw cycles, wherein the freeze portion of each cycle is carried out in liquid nitrogen.
Description
IMMUNO-MODULATORY PROGENITOR (IMP) CELL
Field of the Invention
Described herein is immuno-modulatory progenitor (IMP) cells and their use in therapy. The
invention generally relates to a population of IMP cells, pharmaceutical compositions comprising a
population of IMP cells, a method of producing a population of IMP cells and use of a population of
IMP cells in the manufacture of a medicament for repairing damaged tissue in a patient or treating a
cardiac, bone, cartilage, tendon, ligament, liver, kidney or lung injury or disease in a patient.
Background to the Invention
Mesodermal cells are derived from a number of tissues and act as the supportive structure for
other cell types. Bone marrow for instance is made of both haematopoietic and mesenchymal derived
cells. Two principle mesenchymal cell types have been previously described and characterized, namely
(i) mesenchymal stem cells (MSCs) and their precursors and (ii) mesenchymal precursor cells (MPCs)
found in the bone marrow. Mesenchymal stem cells (MSCs) are multipotent, adult stem cells. MSCs
differentiate to form the different specialised cells found in the skeletal tissues. For example, they can
differentiate into cartilage cells (chondrocytes), bone cells (osteoblasts) and fat cells (adipocytes).
MSCs are used in a variety of therapies, such as the treatment of Age ‐related Macular
Degeneration (AMD) and myocardial infarct. Once administered to the patient, the MSCs typically
migrate (or home) to the damaged tissue and exert their therapeutic effects through paracrine signaling
and by promoting survival, repair and regeneration of the neighbouring cells in the damaged tissue.
Current therapies typically involve the infusion of a mixture of MSC subtypes some of which
do not migrate efficiently to the tissue of interest. This necessitates the use of a high cell ‐dose which
can lead to off ‐target side effects and volume ‐related side effects. MSCs are typically obtained from
bone marrow and so it is difficult to obtain large amounts.
It is an objection of the invention to provide improved or alternative therapies in the form of a
population of IMP cells, pharmaceutical compositions comprising the population of IMP cells, uses of
the population of IMP cells and methods of producing the population of IMP cells and/or to at least
provide the public with a useful choice.
Summary of the Invention
Described herein is a novel cell type that has not been previously identified or isolated, the
immuno-modulatory progenitor cell. This IMP cell is quite distinct and different to both MSCs and
MPCs in its composition, function and characteristics which impart an enhanced immuno-modulatory
capacity.
The inventors have surprisingly identified a new immuno-modulatory progenitor (IMP) cell
having a specific marker expression pattern. In particular, the IMP cell expresses MIC A/B, CD304
(Neuropilin 1), CD178 (FAS ligand), CD289 (Toll-like receptor 9), CD363 (Sphingosinephosphate
receptor 1), CD99, CD181 (C-X-C chemokine receptor type 1; CXCR1), epidermal growth factor
receptor (EGF-R), CXCR2 and CD126, The IMP cell expresses significantly greater amounts of these
markers than a mesencymal stem cell (MSC). The IMP cells described herein can be isolated from
mononuclear cells (MCs), such as peripheral blood MCs. The IMP cells are capable of efficiently
migrating to and repairing damaged tissues. In particular, they are capable of homing, adherence,
transmigration, proliferation, angiogenic effects and paracrine signalling.
Accordingly, in a first aspect, the invention provides a population of immuno-modulatory
progenitor (IMP) cells, wherein
(i) at least 90% of the cells in the population express on their surfaces detectable levels of MIC
A/B,
(ii) at least 60% of the cells in the population express on their surfaces detectable levels of
CD304 (Neuropilin 1),
(iii) at least 45% of the cells in the population express on their surfaces detectable levels of
CD178 (FAS ligand),
(iv) at least 10% of the cells in the population express on their surfaces detectable levels of
CD289 (Toll-like receptor 9),
(v) at least 15% of the population express on their surfaces detectable levels of CD363
(Sphingosinephosphate receptor 1),
(vi) at least 20% of the cells in the population express on their surfaces detectable levels of
CD99,
(vii) at least 80% of the cells in the population express on their surfaces detectable levels of
CD181 (C-X-C chemokine receptor type 1; CXCR1),
(viii) at least 30% of the cells in the population express on their surfaces detectable levels of
epidermal growth factor receptor (EGF-R),
(xi) at least 60% of the cells in the population express on their surfaces detectable levels of
CXCR2, and
(x) at least 5% of the cells in the population express on their surfaces detectable levels of
CD126, and wherein the IMP cells secrete detectable levels of interleukin-6 (IL-6) and
interleukin-8 (IL-8).
In a second aspect, the invention provides a pharmaceutical composition comprising (a) a
population according to the first aspect and (b) a pharmaceutically acceptable carrier or diluent, one or
more liposomes and/or one or more microbubbles.
In a third aspect, the invention provides a method of producing a population of IMP cells
according to the first aspect, comprising (i) culturing mononuclear cells (MCs) for from 15 to 25 days
in a medium comprising platelet lysate, at less than 20% oxygen (O ) and under conditions which allow
the MCs to adhere to induce the MCs to differentiate into IMP cells and (ii) harvesting and culturing
those IMP cells which have an expression pattern as defined in the first aspect and thereby producing a
population according to claim 1, wherein the platelet lysate is produced by subjecting a population of
human platelets to four freeze-thaw cycles, wherein the freeze portion of each cycle is carried out in
liquid nitrogen.
In a fourth aspect, the invention provides a use of a population according to the first aspect or a
pharmaceutical composition according to the second aspect in the manufacture of a medicament for
repairing a damaged tissue in a patient or treating a cardiac, bone, cartilage, tendon, ligament, liver,
kidney or lung injury or disease in a patient.
Described herein is an immuno-modulatory progenitor (IMP) cell, wherein the cell expresses detectable
levels of MIC A/B, CD304 (Neuropilin 1), CD178 (FAS ligand), CD289 (Toll-like receptor 9), CD363
(Sphingosinephosphate receptor 1), CD99, CD181 (C-X-C chemokine receptor type 1; CXCR1),
epidermal growth factor receptor (EGF-R), CXCR2 and CD126.
Also described:
- a population of two or more IMP cells described herein;
- a population of immuno-modulatory progenitor (IMP) cells, wherein
(i) at least 90% of the cells in the population express detectable levels of MIC A/B,
(ii) at least 60% of the cells in the population express detectable levels of CD304 (Neuropilin
(iii) at least 45% of the cells in the population express detectable levels of CD178 (FAS ligand),
(iv) at least 10% of the cells in the population express detectable levels of CD289 (Toll-like
receptor 9),
(v) at least 15% of the population express detectable levels of CD363 (Sphingosinephosphate
receptor 1),
(vi) at least 20% of the cells in the population express detectable levels of CD99,
(vii) at least 80% of the cells in the population express detectable levels of CD181 (C-X-C
chemokine receptor type 1; CXCR1),
(viii) at least 30% of the cells in the population express detectable levels of epidermal growth
factor receptor (EGF-R),
(xi) at least 60% of the cells in the population express detectable levels of CXCR2 and
(x) at least 5% of the cells in the population express detectable levels of CD126;
- a pharmaceutical composition comprising (a) an IMP cell described herein or a population
described herein and (b) a pharmaceutically acceptable carrier or diluent, one or more liposomes and/or
one or more microbubbles;
- a method of producing a population of IMP cells described herein, comprising (a) culturing
mononuclear cells (MCs) under conditions which induce the MCs to differentiate into IMP cells and (b)
harvesting and culturing those IMP cells which have an expression pattern as defined above and
thereby producing a population described herein;
- a method of repairing a damaged tissue in a patient, comprising administering to the patient a
population described herein or a pharmaceutical composition described herein, wherein the population
or composition comprises a therapeutically effective number of cells, and thereby treating the damaged
tissue in the patient;
- a population described hereinor a pharmaceutical composition described hereinfor use in a
method of repairing a damaged tissue in a patient; and
- a population described hereinor a pharmaceutical composition described hereinfor use in a
method of treating a cardiac, bone, cartilage, tendon, ligament, liver, kidney or lung injury or disease in
a patient.
In this specification where reference has been made to patent specifications, other external
documents, or other sources of information, this is generally for the purpose of providing a context for
discussing the features of the invention. Unless specifically stated otherwise, reference to such external
documents is not to be construed as an admission that such documents, or such sources of information,
in any jurisdiction, are prior art, or form part of the common general knowledge in the art.
In the description in this specification reference may be made to subject matter which is not
within the scope of the claims of the current application. That subject matter should be readily
identifiable by a person skilled in the art and may assist in putting into practice the invention as defined
in the claims of this application.
The term “comprising” as used in this specification and claims means “consisting at least in
part of”. When interpreting statements in this specification and claims which include the term
“comprising”, other features besides the features prefaced by this term in each statement can also be
present. Related terms such as “comprise” and “comprised” are to be interpreted in similar manner.
Detailed Description of the Invention
It is to be understood that different applications of the disclosed products and methods may be
tailored to the specific needs in the art. It is also to be understood that the terminology used herein is
for the purpose of describing particular embodiments of the invention only, and is not intended to be
limiting.
In addition, as used in this specification and the appended claims, the singular forms “a”, “an”,
and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example,
reference to “a cell” includes “cells”, reference to “a tissue” includes two or more such tissues,
reference to “a patient” includes two or more such patients, and the like.
All publications, patents and patent applications cited herein, whether supra or infra, are hereby
incorporated by reference in their entirety.
IMP cell
Described herein is an immuno-modulatory progenitor (IMP) cell. The IMP cell expresses
detectable levels of MIC A/B, CD304 (Neuropilin 1), CD178 (FAS ligand), CD289 (Toll-like receptor
9), CD363 (Sphingosinephosphate receptor 1), CD99, CD181 (C-X-C chemokine receptor type 1;
CXCR1), epidermal growth factor receptor (EGF-R), CXCR2 and CD126.
MIC allows adaptation of cells and their immuno-behaviour in an inflammatory context by
decreasing their susceptibility to NK killing.
CD304 (alternate name Neuropilin 1) is a co-receptor for vascular endothelial growth factor
(VEGF) and has roles in angiogenesis, cell survival, migration and invasion.
CD178 (alternate name FAS ligand) maintains cell phenotype and controls differentiation. It is
also capable of inducing proliferation of cells. Although FAS ligand is known primarily in apoptotic
signalling, it has been shown that FAS and FAS ligand expressing cells are resistant to FAS-induced
apoptosis.
CD289 (alternate name Toll-like receptor 9) is involved in the modulation of immune responses
and may facilitate cell migration towards a target tissue.
Sustained activation of CD363 (alternate name is Sphingosinephosphate receptor 1) has
resulted in increased engraftment of cells in-vivo. CD363 also promotes angiogenesis, modulates cell
homing, modulates trafficking and migration of cells and regulates chemotaxis.
CD99 is involved in cell adhesion and transmigration.
There are two classes of interleukin-8 (IL-8) receptors, CXCR1 (or CD181) and CXCR2. Both
receptors bind IL-8 with high affinity, in contrast to the other CXC chemokines. Functionally, CXCR1
and CXCR2 have been shown to play significant roles in proliferation, migration, invasion and
angiogenesis. Damaged tissues release a variety of soluble inflammatory factors, such as macrophage
migration inhibitory factor (MIF) and interleukin-8, and these factors may attract the IMP cells
described herein (and other inflammatory cells) to the damaged tissue though binding to binding
CXCR1 and/or CXCR2.
EGF-R is involved in cell migration, adhesion and proliferation.
CD126 (alternate name is IL-6R1) increases immune-privilege
The IMP cells described herein have numerous advantages. The key advantages will be
summarized here. However, further advantages will become apparent from the discussion below.
The IMP cells described herein may advantageously be used to repair damaged tissues in
patients. The IMP cells are capable of efficiently migrating (or homing) to a damaged tissue and
exerting anti-inflammatory effects in the tissue. This is discussed in more detail below. One of the
most important abilities of the IMP cells is to migrate (or home) to injured sites, which involves
chemotaxis. This is based on chemokine-signalling and utilises mechanisms such as rolling, adhesion
and transmigration. The anti-inflammatory effects of the IMP cells promote survival, repair and
regeneration of the neighbouring cells in the damaged tissue. The cells are also able to exert paracrine
effects such as the secretion of angiogenic, chemotactic and anti-apoptotic factors. This is also
discussed in more detail below.
As discussed in more detail below, the IMP cells are produced from mononuclear cells (MCs),
such as peripheral MCs, taken from an individual, such as a human individual. Since the IMP cells are
produced from MCs, they may be produced easily (such as from peripheral blood) and may be
autologous for the patient to be treated and thereby avoid the risk of immunological rejection by the
patient.
It is possible, in principle, to produce an unlimited number of IMP cells from a single
individual, since various samples of MCs (i.e. various samples of blood) may be obtained. It is
certainly possible to produce very large numbers of IMP cells from a single individual. The IMP cells
described herein can therefore be made in large numbers.
The IMP cells described herein are produced in clinically relevant conditions, for instance in the
absence of trace amounts of endotoxins and other environmental contaminants, as well as animal
products such as fetal calf serum. This makes the IMP cells described herein particularly suitable for
administration to patients.
Since the IMP cells described herein are produced from MCs, they are substantially
homologous and may be autologous. They also avoid donor-to-donor variation, which frequently
occurs with MSCs. Numerous populations of IMP cells described herein can be produced from a single
sample taken from the patient before any other therapy, such as chemotherapy or radiotherapy, has
begun. Therefore, the IMP cells described herein can avoid any of the detrimental effects of those
treatments.
The IMP cells described herein can be made quickly. IMP cells can be produced from MCs in
less than 30 days, such as in about 22 days.
The production of IMP cells from MCs avoids the moral and ethical implications involved with
using mesenchymal stem cells MSCs derived from human embryonic stem cells (hESCs).
The IMP cells described herein are typically produced from human MCs. The IMP cells
described herein are therefore typically human. Alternatively, the IMP cells may be produced from
MCs from other animals or mammals, for instance from commercially farmed animals, such as horses,
cattle, sheep or pigs, from laboratory animals, such as mice or rats, or from pets, such as cats, dogs,
rabbits or guinea pigs.
The IMP cells described herein can be identified as immunomodulatory progenitor cells using
standard methods known in the art, including expression of lineage restricted markers, structural and
functional characteristics. The IMP cells will express detectable levels of cell surface markers known
to be characteristic of IMPs. These are discussed below.
The IMP cells described herein are capable of successfully completing differentiation assays in
vitro to confirm that they are of mesodermal lineage. Such assays include, but are not limited to,
adipogenic differentiation assays, osteogenic differentiation assays and neurogenic differentiation
assays (Zaim M et al Ann Hematol. 2012 Aug;91(8):1175-86).
The IMP cells described herein are not stem cells. In particular, they are not MSCs. They are
terminally differentiated. Although they can be forced under the right conditions in vitro to
differentiating, for instance into cartilage or bone cells, they typically do not differentiate in vivo. The
IMP cells described herein have their effects by migrating to the damaged tissue and exerting paracrine
signalling in the damaged tissue. In particular, the IMP cells are preferably capable of inducing anti-
flammatory effects in the damaged tissue. This is discussed in more detail below.
The IMP cells described herein are typically characterised by a spindle-shaped morphology.
The IMP cells are typically fibroblast-like, i.e. they have a small cell body with a few cell processes
that are long and thin. The cells are typically from about 10 to about 20 µm in diameter.
The IMP cells described herein are distinguished from known cells, including MSCs, via their
marker expression pattern. The IMPs express detectable levels of MIC A/B, CD304 (Neuropilin 1),
CD178 (FAS ligand), CD289 (Toll-like receptor 9), CD363 (Sphingosinephosphate receptor 1),
CD99, CD181 (C-X-C chemokine receptor type 1; CXCR1), epidermal growth factor receptor (EGF-
R), CXCR2 and CD126. The IMPs preferably express an increased amount of these markers compared
with MSCs. This can be determined by comparing the expression level/amount of the markers in an
IMP described herein with the expression level/amount in an MSC using the same technique under the
same conditions. Suitable MSCs are commercially available. The MSC used for comparison is
preferably a human MSC. Human MSCs are commercially available from Mesoblast® Ltd, Osiris
Therapeutics® Inc. or Lonza®. The human MSC is preferably obtained from Lonza®. Such cells were
used for the comparison in the Example. The MSC may be derived from any of the animals or
mammals discussed above.
The IMP cells preferably express an increased amount of one or more of MIC A/B, CD304
(Neuropilin 1), CD178 (FAS ligand), CD289 (Toll-like receptor 9), CD363 (Sphingosinephosphate
receptor 1), CD99, CD181 (C-X-C chemokine receptor type 1; CXCR1), epidermal growth factor
receptor (EGF-R), CXCR2 and CD126 compared with a MSC. The IMP cells preferably express an
increased amount of all of the ten markers compared with a MSC.
Standard methods known in the art may be used to determine the detectable expression or
increased expression of various markers discussed above (and below). Suitable methods include, but
are not limited to, immunocytochemistry, immunoassays, flow cytometry, such as fluorescence
activated cells sorting (FACS), and polymerase chain reaction (PCR), such as reverse transcription PCR
(RT-PCR). Suitable immunoassays include, but are not limited to, Western blotting, enzyme-linked
immunoassays (ELISA), enzyme-linked immunosorbent spot assays (ELISPOT assays), enzyme
multiplied immunoassay techniques, radioallergosorbent (RAST) tests, radioimmunoassays,
radiobinding assays and immunofluorescence. Western blotting, ELISAs and RT-PCR are all
quantitative and so can be used to measure the level of expression of the various markers if present.
The use of high-throughput FACS (HT-FACS) is disclosed in the Example. The expression or
increased expression of any of the markers disclosed herein is preferably done using HT-FACS.
Antibodies and fluorescently-labelled antibodies for all of the various markers discussed herein are
commercially-available.
The IMP cells described herein preferably demonstrate an antibody mean fluorescence intensity
(MFI) of at least 330, such as at least 350 or at least 400, for MIC A/B, an MFI of at least 210, such as
at least 250 or at least 300, for CD304 (Neuropilin 1), an MFI of at least 221, such as at least 250 or at
least 300, for CD178 (FAS ligand), an MFI of at least 186, such as at least 200 or at least 250, for
CD289 (Toll-like receptor 9), an MFI of at least 181, such as at least 200 or at least 250, for CD363
(Sphingosinephosphate receptor 1), an MFI of at least 184, such as at least 200 or at least 250, for
CD99, an MFI of at least 300, such as at least 350 or at least 400, for CD181 (C-X-C chemokine
receptor type 1; CXCR1), an MFI of at least 173, such as at least 200 or at least 250, for epidermal
growth factor receptor (EGF-R), an MFI of at least 236, such as at least 250 or at least 300, for CXCR2
and an MFI of at least 160, such as at least 200 or at least 250, for CD126. Mean fluorescent intensity
(MFI) is a measure of intensity, time average energy flux measured in watts per square metre. It is an
SI unit. The MFI for each marker is typically measured using HT-FACS. The MFI for each marker is
preferably measured using HT-FACS as described in the Example.
In addition to the ten markers specified above, the IMP cells described herein typically express
detectable levels of one or more of the other markers shown in Table 1 in the Example. The IMP cells
may express detectable levels of any number and combination of those markers.
The IMP cells preferably express detectable levels of one or more of CD267, CD47,
CD51/CD61, CD49f, CD49d, CD146, CD340, Notch2, CD49b, CD63, CD58, CD44, CD49c, CD105,
CD166, HLA-ABC, CD13, CD29, CD49e, CD73, CD81, CD90, CD98, CD147, CD151 and CD276.
The IMP cells more preferably express detectable levels of one or more of CD10, CD111, CD267,
CD47, CD273, CD51/CD61, CD49f, CD49d, CD146, CD55, CD340, CD91, Notch2, CD175s, CD82,
CD49b, CD95, CD63, CD245, CD58, CD108, B2-microglobulin, CD155, CD298, CD44, CD49c,
CD105, CD166, CD230, HLA-ABC, CD13, CD29, CD49e, CD59, CD73, CD81, CD90, CD98,
CD147, CD151 and CD276. The IMP cells may express detectable levels of any number and
combination of these markers. The IMP cells preferably express detectable levels of all of these
markers.
The IMP cells preferably express detectable levels of one or more of CD156b, CD61, CD202b,
CD130, CD148, CD288, CD337, SSEA-4, CD349 and CD140b. The IMP cells more preferably
express detectable levels of one or more of CD156b, CD61, CD202b, CD130, CD148, CD288, CD337,
SSEA-4, CD349, CD140b, CD10, CD111, CD267, CD47, CD273, CD51/CD61, CD49f, CD49d,
CD146, CD55, CD340, CD91, Notch2, CD175s, CD82, CD49b, CD95, CD63, CD245, CD58, CD108,
B2-microglobulin, CD155, CD298, CD44, CD49c, CD105, CD166, CD230, HLA-ABC, CD13, CD29,
CD49e, CD59, CD73, CD81, CD90, CD98, CD147, CD151 and CD276. The IMP cells may express
detectable levels of any number and combination of these markers. The IMP cells preferably express
detectable levels of all of these markers.
The IMP cells preferably express detectable levels of one or more of CD72, CD133, CD192,
CD207, CD144, CD41b, FMC7, CD75, CD3e, CD37, CD158a, CD172b, CD282, CD100, CD94,
CD39, CD66b, CD158b, CD40, CD35, CD15, PAC-1, CLIP, CD48, CD278, CD5, CD103, CD209,
CD3, CD197, HLA-DM, CD20, CD74, CD87, CD129, CDw329, CD57, CD163, TPBG, CD206,
CD243 (BD), CD19, CD8, CD52, CD184, CD107b, CD138, CD7, CD50, HLA-DR, CD158e2, CD64,
DCIR, CD45, CLA, CD38, CD45RB, CD34, CD101, CD2, CD41a, CD69, CD136, CD62P, TCR alpha
beta, CD16b, CD1a, ITGB7, CD154, CD70, CDw218a, CD137, CD43, CD27, CD62L, CD30, CD36,
CD150, CD66, CD212, CD177, CD142, CD167, CD352, CD42a, CD336, CD244, CD23, CD45RO,
CD229, CD200, CD22, CDH6, CD28, CD18, CD21, CD335, CD131, CD32, CD157, CD165, CD107a,
CD1b, CD332, CD180, CD65 and CD24. The IMP cells may express detectable levels of any number
and combination of these markers. The IMP cells preferably express detectable levels of all of these
markers.
The IMP cells described herein are preferably capable of migrating to a specific, damaged
tissue in a patient. In other words, when the cells are administered to a patient having a damaged
tissue, the cells are capable of migrating (or homing) to the damaged tissue. This is advantageous
because it means that the cells can be infused via standard routes, for instance intravenously, and will
then target the site of damage. The cells do not have to be delivered to the damaged tissue. The
damage may be due to injury or disease as discussed in more detail below.
The specific tissue is preferably cardiac, bone, cartilage, tendon, ligament, liver, kidney or lung
tissue. This applies not only to migration, but also adherence, transmigration, proliferation, anti-
inflammatory effects and angiogenesis as discussed in more detail below.
The ability of the IMP cells described herein to migrate to damaged tissue may be measured
using standard assays known in the art. Suitable methods include, but are not limited to, genomic
reverse transcription polymerase chain reaction (RT-PCR with or without reporter genes) and labelling
techniques.
RT-PCR is the most straightforward and simple means to trace the IMP cells described herein
within a patient. A transduced transgene or individual donor markers can be used for this purpose and
transplanted cell-specific signals have been obtained in several patient studies. The results are
generally semi-quantitative.
Alternatively, the IMP cells described herein may be stained with a dye of interest, such as a
fluorescent dye, and may be monitored in the patient via the signal from the dye. Such methods are
routine in the art.
Migration (or homing) is typically determined by measuring the number of cells that arrive at
the damaged tissue. It may also be measured indirectly by observing the numbers of cells that have
accumulated in the lungs (rather than the damaged tissue).
Damaged heart tissue releases inflammatory chemokines and cytokines, such as stromal cell ‐
derived factor ‐1 (SDF ‐1), interleukin ‐8 (IL ‐8), tumor necrosis factor ‐alpha (TNF ‐alpha), granulocyte ‐
colony ‐stimulating factor (G ‐CSF), vascular endothelial growth factor (VEGF) and hepatocyte growth
factor (HGF). In addition, myocardial infarct increases the levels of VEGF and erythropoietin (EPO).
CXCR4 binds to its ligand SDF ‐1 and so IMP cells described herein expressing CXCR4 will migrate
towards the gradient of SDF ‐1 generated by the damaged heart tissue. Other damaged tissues, such as
bone, also release SDF-1. If the specific, damaged tissue is cardiac tissue, the IMP cells described
herein preferably express detectable levels of CXCR4 or express an increased amount of CXCR4
compared with MSCs.
If the specific, damaged tissue is bone tissue, the IMP cells described herein preferably express
detectable levels of TGF-beta 3, bone morphogenetic protein-6 (BMP-6), SOX-9, Collagen-2, CD117
(c-kit), chemokine (C-C motif) ligand 12 (CCL12), CCL7, interleukin-8 (IL-8), platelet-derived growth
factor-A (PDGF-A), PDGF-B, PDGF-C, PDGF-D, macrophage migration inhibitory factor (MIF), IGF-
1, hepatocyte growth factor (HGF), PDGF-Rα, PDGF-Rβ, CXCR4, C-C chemokine receptor type 1
(CCR1), IGF-1 receptor (IGF-1R), hepatocyte growth factor receptor (HGFR), CXCL12 and
NFkappaB. The bone-homing IMP cells described herein preferably express an increased amount of
one or more of, or even all of, these factors compared with mesenchymal stem cells MSCs. The
detectable expression of these markers may be measured as discussed above.
The IMP cells described herein are preferably capable of adhering to a specific, damaged tissue
in a patient. Adherence and adhesion assay are known in the art (Humphries, Methods Mol Biol.
2009;522:203-10).
The IMP cells described herein are preferably capable of transmigrating through the vascular
endothelium to a specific, damaged tissue in a patient. Transmigration assays are known in the art
(Muller and Luscinskas, Methods Enzymol. 2008; 443: 155–176).
The IMP cells described herein are preferably capable of proliferating in a specific, damaged
tissue in a patient. Cell proliferation assays are well known in the art. Such assays are commercially
available, for instance from Life Technologies®.
The IMP cells described herein are preferably capable of promoting angiogenesis in a specific,
damaged tissue in a patient. Angiogenesis assays are known in the art (Auerback et al., Clin Chem.
2003 Jan;49(1):32-40).
The IMP cells described herein are preferably capable of having anti-inflammatory effects in a
damaged tissue of a patient. The ability of the IMP cells described herein to have anti-inflammatory
effects may also be measured using standard assays known in the art. Suitable methods include, but are
not limited to, enzyme-linked immunosorbent assays (ELISAs) for the secretion of cytokines, enhanced
mixed leukocyte reactions and up-regulation of co-stimulatory molecules and maturation markers,
measured by flow cytometry. Specific methods that may be used are disclosed in the Example. The
cytokines measured are typically interleukins, such as interleukin-8 (IL-8), selectins, adhesion
molecules, such as Intercellular Adhesion Molecule-1 (ICAM-1), and chemoattractant proteins, such as
monocyte chemotactic protein-1 (MCP-1) and tumour necrosis factor alpha (TNF-alpha). Assays for
these cytokines are commercially-available. Anti-inflammatory factors are preferably detected and
measured using the Luminex® assay described in the Examples. Such assays are commercially
available from Life Technologies®.
The IMP cells preferably secrete detectable levels of one or more of interleukin-6 (IL-6), IL-8,
C-X-C motif chemokine 10 (CXCL10; interferon gamma-induced protein 10; IP-10), Chemokine (C-C
motif) ligand 2 (CCL2; monocyte chemotactic protein-1; MCP-1) and Chemokine (C-C motif) ligand 5
(CCL5; regulated on activation, normal T cell expressed and secreted; RANTES). The IMP cells may
secrete any number and combination of these factors. The IMP cells preferably secrete all of these
markers.
The IMP cells preferably secrete an increased amount of one or more of IL-6, IL-8, IP-10,
MCP-1 and RANTES compared with a MSC. The IMP cells may secrete an increased amount of any
number and combination of these factors. The IMP cells preferably secrete an increased amount of all
of these markers.
The IMP cells preferably secrete a decreased amount of interleukin-10 (IL-10) and/or IL-12
compared with a mesenchymal stem cell MSC. IL-10 and IL-12 are pro-inflammatory cytokines.
The IMP cells described herein are more preferably capable of migrating to a damaged tissue in
a patient and having anti-inflammatory effects in the damaged tissue. This allows the damage to be
repaired effectively and reduces the number of cells that need to be administered.
The IMP cells described herein will express a variety of different other markers over and above
those discussed above. Some of these will assist the IMP cells will their ability to migrate to a
damaged tissue and have anti-inflammatory effects once there. Any of the IMP cells described herein
further express detectable levels of one or more of (i) insulin-like growth factor-1 (IGF-1), (ii) IGF-1
receptor; (iii) C-C chemokine receptor type 1 (CCR1), (iv) stromal cell-derived factor-1 (SDF-1), (v)
hypoxia-inducible factor-1 alpha (HIF-1 alpha), (vi) Akt1 and (vii) hepatocyte growth factor (HGF)
and/or granulocyte colony-stimulating factor (G-CSF).
IGF ‐1 receptors promote migration capacity towards an IGF ‐1 gradient. One of the
mechanisms by which IGF ‐1 increases migration is by up ‐regulating CXCR4 on the surface of the
cells, which makes them more sensitive to SDF ‐1 signaling. This is discussed above.
CCR1 is the receptor for CCL7 (previously known as MCP3) increases homing and
engraftment capacity of MSCs (and so would be expected to have the same effect for the IMP cells
described herein) and can increase the capillary density in injured myocardium through paracrine
signalling.
HIF-1 alpha activates pathways that increase oxygen delivery and promote adaptive pro ‐
survival responses. Among the many target genes of HIF-1 alpha are erythropoietin (EPO), endothelin
and VEGF (with its receptor Flk ‐1). IMP cells that express or express an increased amount of HIF ‐
1alpha will have upregulated expression of paracrine stimuli of for example several vasculogenic
growth factors that may promote a more therapeutic subtype. As described in more detail below, the
IMP cells described herein can be preconditioned into a more therapeutic subtype by culturing them
under hypoxic conditions (less than 20% oxygen), such as for example about 2% or about 0% oxygen.
Akt1 is an intracellular serine/threonine protein kinase that plays a key role in multiple cellular
processes such as glucose metabolism, cell proliferation, apoptosis, transcription and cell migration.
Overexpression of Akt1 has been shown to prevent rat MSCs from undergoing apoptosis and will have
the same effect in the IMP cells described herein. Protection from apoptosis will enhance the
therapeutic effect of the IMP cells.
The overexpression of HGF by MSCs has been shown to prevent post ‐ischemic heart failure by
inhibition of apoptosis via calcineurin ‐mediated pathway and angiogenesis. HGF and G-CSF exhibit
synergistic effects in this regard. MSCs that have a high expression of HGF and its receptor c ‐met also
have an increased migratory capacity into the damaged tissue, achieved through hormonal, paracrine
and autocrine signaling. The same will be true for the IMP cells described herein expressing HGF
and/or G-CSF.
The IMP cells may express detectable levels off one or more of (i) to (vii) defined above. The
IMP cells described herein preferably express an increased amount of one or more of (i) to (vii)
compared with MSCs. Quantitative assays for cell markers are described above. The detectable
expression of these markers and their level of expression may be measured as discussed above.
Any of the IMP cells described herein may express detectable levels of one or more of (i)
vascular endothelial growth factor (VEGF), (ii) transforming growth factor beta (TGF-beta), (iii)
insulin-like growth factor-1 (IGF-1), (iv) fibroblast growth factor (FGF), (v) tumour necrosis factor
alpha (TNF-alpha), (vi) interferon gamma (IFN-gamma) and (vii) interleukin-1 alpha (IL-1 alpha).
Conditioned medium from cells overexpressing VEGF has been shown to alleviate heart failure in a
hamster model. Hence, the IMP cells of the invention which express or express an increased amount of
VEGF will have the same effect of damaged cardiac tissue.
The IMP cells may express detectable levels of one or more of (i) to (vii). The IMP cells
described herein may express an increased amount of one or more of (i) to (vii) compared with MSCs.
Quantitative assays for cell markers are described above. The detectable expression of these markers
and their level of expression may be measured as discussed above.
In both sets of definitions of (i) to (vii) given above, any combination of one or more of (i) to
(vii) may be expressed or expressed in an increased amount. For instance, for each definition of (i) to
(vii), the IMP cells may express detectable levels of, or express an increased amount of, (i); (ii); (iii);
(iv); (v); (vi); (vii); (i) and (ii); (i) and (iii); (i) and (iv); (i) and (v); (i) and (vi); (i) and (vii); (ii) and
(iii); (ii) and (iv); (ii) and (v); (ii) and (vi); (ii) and (vii); (iii) and (iv); (iii) and (v); (iii) and (vi); (iii)
and (vii); (iv) and (v); (iv) and (vi); (iv) and (vii); (v) and (vi); (v) and (vii); (vi) and (vii); (i), (ii) and
(iii); (i), (ii) and (iv); (i), (ii) and (v); (i), (ii) and (vi); (i), (ii) and (vii); (i,), (iii) and (iv); (i), (iii) and
(v); (i), (iii) and (vi); (i), (iii) and (vii); (i), (iv) and (v); (i), (iv) and (vi); (i), (iv) and (vii); (i), (v) and
(vi); (i), (v) and (vii); (i), (vi) and (vii); (ii), (iii) and (iv); (ii), (iii) and (v); (ii), (iii) and (vi); (ii), (iii)
and (vii); (ii), (iv) and (v); (ii), (iv) and (vi); (ii), (iv) and (vii); (ii), (v) and (vi); (ii), (v) and (vii); (ii),
(vi) and (vii); (iii), (iv) and (v); (iii), (iv) and (vi); (iii), (iv) and (vii); (iii), (v) and (vi); (iii), (v) and
(vii); (iii), (vi) and (vii); (iv), (v) and (vi); (iv), (v) and (vii); (iv), (vi) and (vii); (v), (vi) and (vii); (i),
(ii), (iii) and (iv); (i), (ii), (iii) and (v); (i), (ii), (iii) and (vi); (i), (ii), (iii) and (vii); (i), (ii), (iv) and (v);
(i), (ii), (iv) and (vi); (i), (ii), (iv) and (vii); (i), (ii), (v) and (vi); (i), (ii), (v) and (vii); (i), (ii), (vi) and
(vii); (i), (iii), (iv) and (v); (i), (iii), (iv) and (vi); (i), (iii), (iv) and (vii); (i), (iii), (v) and (vi); (i), (iii),
(v) and (vii); (i), (iii), (vi) and (vii); (i), (iv), (v) and (vi); (i), (iv), (v) and (vii); (i), (iv), (vi) and (vii);
(i), (v), (vi) and (vii); (ii), (iii), (iv) and (v); (ii), (iii), (iv) and (vi); (ii), (iii), (iv) and (vii); (ii), (iii), (v)
and (vi); (ii), (iii), (v) and (vii); (ii), (iii), (vi) and (vii); (ii), (iv), (v) and (vi); (ii), (iv), (v) and (vii); (ii),
(iv), (vi) and (vii); (ii), (v), (vi) and (vii); (iii), (iv), (v) and (vi); (iii), (iv), (v) and (vii); (iii), (iv), (vi)
and (vii); (iii), (v), (vi) and (vii); (iv), (v), (vi) and (vii); (i), (ii), (iii), (iv) and (v); (i), (ii), (iii), (iv) and
(vi); (i), (ii), (iii), (iv) and (vii); (i), (ii), (iii), (v) and (vi); (i), (ii), (iii), (v) and (vii); (i), (ii), (iii), (vi)
and (vii); (i), (ii), (iv), (v) and (vi); (i), (ii), (iv), (v) and (vii); (i), (ii), (iv), (vi) and (vii); (i), (ii), (v), (vi)
and (vii); (i), (iii), (iv), (v) and (vi); (i), (iii), (iv), (v) and (vii); (i), (iii), (iv), (vi) and vii); (i), (iii), (v),
(vi) and (vii); (i), (iv), (v), (vi) and (vii); (ii), (iii), (iv), (v) and (vi); (ii), iii), (iv), (v) and (vii); (ii), (iii),
(iv), (vi) and (vii); (ii), (iii), (v), (vi) and (vii); (ii), (iv), (v), (vi) and (vii); (iii), (iv), (v), (vi) and vii);
(i), (ii), (iii), (iv), (v) and (vi); (i), (ii), (iii), (iv), (v) and (vii); (i), (ii), (iii), (iv), (vi) and (vii); (i), (ii),
(iii), (v), (vi) and (vii); (i), (ii), (iv), (v), (vi) and (vii); (i), (iii), (iv), (v), (vi) and (vii); (ii), (iii), (iv), (v),
(vi) and (vii); or (i), (ii), (iii), (iv), (v), (vi) and (vii). The combinations for each definition of (i) to (vii)
are independently selectable from this list.
In addition to any of the markers discussed above, the IMP cells described herein preferably
also express detectable levels of, LIF and/or platelet-derived growth factor (PDGF) receptors. The IMP
cells described herein preferably express an increased amount of LIF and/or platelet-derived growth
factor (PDGF) receptors compared with mesenchymal stem cells. The PDGF receptors are preferably
PDGF-A receptors and/or PSDGF-B receptors. MSCs that have high expression of these receptors can
migrate effectively into areas in which platelets have been activated, such as wounds and thrombotic
vessels. The same will be true of IMP cells expressing or expressing an increased amount of the
receptors.
The IMP cells described herein are preferably autologous. In other words, the cells are
preferably derived from the patient into which the cells will be administered. Alternatively, the IMP
cells are preferably allogeneic. In other words, the cells are preferably derived from a patient that is
immunologically compatible with the patient into which the cells will be administered.
An IMP cell described herein may be isolated, substantially isolated, purified or substantially purified.
The IMP cell is isolated or purified if it is completely free of any other components, such as culture
medium, other cells described herein or other cell types. The IMP cell is substantially isolated if it is
mixed with carriers or diluents, such as culture medium, which will not interfere with its intended use.
Alternatively, the IMP cell described herein may be present in a growth matrix or immobilized on a
surface as discussed below.
IMP cells described herein may be isolated using a variety of techniques including antibody-
based techniques. Cells may be isolated using negative and positive selection techniques based on the
binding of monoclonal antibodies to those surface markers which are present on the IMP cell (see
above). Hence, the IMP cells may be separated using any antibody-based technique, including
fluorescent activated cell sorting (FACS) and magnetic bead separation.
As discussed in more detail below, the IMP cells may be treated ex vivo. Thus the cells may be
loaded or transfected with a therapeutic or diagnostic agent and then used therapeutically in the
methods described herein.
Population of the invention
The invention also provides a population of two or more IMP cells described herein. Any
number of cells may be present in the population. The population of the invention preferably comprises
at least about 5 x 10 IMP cells described herein. The population more preferably comprises at least
6 6 6 6
about 1 x 10 , at least about 2 x 10 , at least about 2.5 2 x 10 , at least about 5 x 10 , at least about 1 x
7 7 7 8 8
, at least about 2 x 10 , at least about 5 x 10 , at least about 1 x 10 or at least about 2 x 10 IMP
cells described herein. In some instances, the population may comprise at least about 1.0 x 10 , at least
8 9 10 11
about 1.0 x 10 , at least about 1.0 x 10 , at least about 1.0 x 10 , at least about 1.0 x 10 or at about
least 1.0 x 10 IMP cells described herein or even more.
The population comprising two or more IMP cells described herein may comprise other cells in
addition to the IMP cells described herein. However, at least 70% of the cells in the population are
preferably IMP cells described herein. More preferably, at least about 75%, at least about 80%, at least
about 85%, at least about 90%, at least about 97%, at least about 98% or at least about 99% of the cells
in the population are IMP cells described herein.
The invention also provides specific populations of IMP cells. The invention provides a
population of immuno-modulatory progenitor (IMP) cells, wherein
(i) at least 90%, preferably at least 97% and more preferably at least 97.1%, of the cells in the
population express detectable levels of MIC A/B,
(ii) at least 60%, preferably at least 65% and more preferably at least 65.2%, of the cells in the
population express detectable levels of CD304 (Neuropilin 1),
(iii) at least 45%, preferably at least 51% and more preferably at least 51.6%, of the cells in the
population express detectable levels of CD178 (FAS ligand),
(iv) at least 10%, preferably at least 11% and more preferably at least 11.3%, of the cells in the
population express detectable levels of CD289 (Toll-like receptor 9),
(v) at least 15%, preferably at least 18% and more preferably at least 18.7%, of the population
express detectable levels of CD363 (Sphingosinephosphate receptor 1),
(vi) at least 20%, preferably at least 24% and more preferably at least 24.8%, of the cells in the
population express detectable levels of CD99,
(vii) at least 80%, preferably at least 85%, of the cells in the population express detectable
levels of CD181 (C-X-C chemokine receptor type 1; CXCR1),
(viii) at least 30%, preferably at least 33% and more preferably at least 33.3%, of the cells in
the population express detectable levels of epidermal growth factor receptor (EGF-R),
(xi) at least 60%, preferably at least 68% and more preferably at least 68.8%, of the cells in the
population express detectable levels of CXCR2 and
(x) at least 5%, preferably at least 7% and more preferably at least 7.05%, of the cells in the
population express detectable levels of CD126.
The cells in these preferred populations may further express detectable levels of any of the
markers discussed above with reference to the IMP described herein. The cells in the these preferred
populations may have any of the advantageous properties of the IMP cells discussed above.
At least 90%, such as at least 95%, of the cells in the population preferably express detectable
levels of one or more of CD10, CD111, CD267, CD47, CD273, CD51/CD61, CD49f, CD49d, CD146,
CD55, CD340, CD91, Notch2, CD175s, CD82, CD49b, CD95, CD63, CD245, CD58, CD108, B2-
microglobulin, CD155, CD298, CD44, CD49c, CD105, CD166, CD230, HLA-ABC, CD13, CD29,
CD49e, CD59, CD73, CD81, CD90, CD98, CD147, CD151 and CD276. At least 90%, such as at least
95%, of the cells in the population may express detectable levels of any number and combination of
these markers. At least 90%, such as at least 95%, of the cells in the population preferably express
detectable levels of all of these markers.
At least 80%, such as at least 85%, of the cells in the population preferably express detectable
levels of one or more of CD156b, CD61, CD202b, CD130, CD148, CD288, CD337, SSEA-4, CD349
and CD140b. At least 80%, such as at least 85%, of the cells in the population may express detectable
levels of any number and combination of these markers. At least 80%, such as at least 85%, of the cells
in the population preferably express detectable levels of all of these markers.
At least 70%, such as at least 75%, of the cells in the population preferably express detectable
levels of one or more of CD318, CD351, CD286, CD46, CD119 and CD132. At least 70%, such as at
least 75%, of the cells in the population may express detectable levels of any number and combination
of these markers. At least 70%, such as at least 75%, of the cells in the population preferably express
detectable levels of all of these markers.
1% or fewer, such as 0.5% or fewer, of the cells in the population preferably express detectable
levels of one or more of CD72, CD133, CD192, CD207, CD144, CD41b, FMC7, CD75, CD3e, CD37,
CD158a, CD172b, CD282, CD100, CD94, CD39, CD66b, CD158b, CD40, CD35, CD15, PAC-1,
CLIP, CD48, CD278, CD5, CD103, CD209, CD3, CD197, HLA-DM, CD20, CD74, CD87, CD129,
CDw329, CD57, CD163, TPBG, CD206, CD243 (BD), CD19, CD8, CD52, CD184, CD107b, CD138,
CD7, CD50, HLA-DR, CD158e2, CD64, DCIR, CD45, CLA, CD38, CD45RB, CD34, CD101, CD2,
CD41a, CD69, CD136, CD62P, TCR alpha beta, CD16b, CD1a, ITGB7, CD154, CD70, CDw218a,
CD137, CD43, CD27, CD62L, CD30, CD36, CD150, CD66, CD212, CD177, CD142, CD167, CD352,
CD42a, CD336, CD244, CD23, CD45RO, CD229, CD200, CD22, CDH6, CD28, CD18, CD21,
CD335, CD131, CD32, CD157, CD165, CD107a, CD1b, CD332, CD180, CD65 and CD24. 1% or
fewer, such as 0.5% or fewer, of the cells in the population may express detectable levels of any
number and combination of these markers. 1% or fewer, such as 0.5% or fewer, of the cells in the
population preferably express detectable levels of all of these markers.
In any of the embodiments above where populations are defined with reference to % of cells
expressing certain markers, the populations preferably comprise at least 5,000 cells, such as at least
6,000, at least 7,000, at least 8,000, at least 9,000, at least 10,000, at least 20,000, at least 30,000 or at
least 40,000 cells. These populations may comprise any of the number of cells discussed above.
Any of the populations of cells disclosed herein may be diluted with other cells before use. For
instance, the population may be combined with patient blood, mononuclear cells (MCs), MSCs,
progenitor cells of the mesodermal lineage (PMLs) or a combination thereof. PMLs are disclosed in
(published as ).
The populations of the invention are advantageous for therapy as discussed below. This ability
to produce populations comprising large numbers of IMP cells described herein is one of the key
advantages of the invention. The invention allows the treatment of patients with a population of cells
of which most, if not all, migrate efficiently to the tissue of interest and have anti-inflammatory effects
once there. This allows the use of a low cell ‐dose and avoids off ‐target side effects and volume ‐related
side effects.
The population of the invention is preferably homologous. In other words, all of the IMP cells
in the population are preferably genotypically and phenotypically identical. The population is
preferably autologous or allogeneic as defined above.
However, the population can also be semi-allogeneic. Semi-allogeneic populations are
typically produced from mononuclear cells from two or more patients that are immunologically
compatible with the patient into which the population will be administered. In other words, all of the
cells in the population are preferably genetically identical or sufficiently genetically identical that the
population is immunologically compatible with the patient into which the population will be
administered. Since the IMP cells described herein may be derived from a patient, they may be
autologous with the patient to be treated (i.e. genetically identical with the patient or sufficiently
genetically identical that they are compatible for administration to the patient).
The population of the invention may be isolated, substantially isolated, purified or substantially
purified. A population is isolated or purified if it is completely free of any other components, such as
culture medium and other cells. A population is substantially isolated if it is mixed with carriers or
diluents, such as culture medium, which will not interfere with its intended use. Other carriers and
diluents are discussed in more detail below. A substantially isolated or substantially purified
population does not comprise cells other than the IMP cells described herein. In some embodiments,
the population of the invention may be present in a growth matrix or immobilized on a surface as
discussed below.
The population is typically cultured in vitro. Techniques for culturing cells are well known to
a person skilled in the art. The cells are may be cultured under standard conditions of 37 °C, 5% CO2
in medium without serum. The cells are preferably cultured under low oxygen conditions as discussed
in more detail below. The cells may be cultured in any suitable flask or vessel, including wells of a
flat plate such as a standard 6 well plate. Such plates are commercially available from Fisher
scientific, VWR suppliers, Nunc, Starstedt or Falcon. The wells typically have a capacity of from
about 1ml to about 4ml.
The flask, vessel or wells within which the population is contained or cultured may be modified
to facilitate handling of the IMP cells. For instance, the flask, vessel or wells may be modified to
facilitate culture of the cells, for instance by including a growth matrix. The flask, vessel or wells may
be modified to allow attachment of the IMP cells or to allow immobilization of the IMP cells onto a
surface. One or more surfaces may be coated with extracellular matrix proteins such as laminin or
collagen or any other capture molecules that bind to the cells and immobilize or capture them on the
surface(s).
The population may be modified ex vivo using any of the techniques described herein. For
instance, the population may be transfected or loaded with therapeutic or diagnostics agents. The
population may then be used in the methods of treatment discussed in more detail below.
Method of producing an IMP cell described herein
The invention also provides a method for producing a population of the invention. The method
involves culturing mononuclear cells (MCs) under conditions which induce the MCs to differentiate
into IMP cells. The method then involves harvesting and culturing the IMP cells which expresses
detectable levels of MIC A/B, CD304 (Neuropilin 1), CD178 (FAS ligand), CD289 (Toll-like receptor
9), CD363 (Sphingosinephosphate receptor 1), CD99, CD181 (C-X-C chemokine receptor type 1;
CXCR1), epidermal growth factor receptor (EGF-R), CXCR2 and CD126. The harvested cells may
express detectable levels of or increased amounts of any of the markers and factors described above
with reference to the cells described herein.
Mononuclear cells (MCs) and methods of isolating them are known in the art. The MCs may
be primary MCs isolated from bone marrow. The MCs are preferably peripheral blood MCs (PBMCs),
such as lymphocytes, monocytes and/or macrophages. PBMCs can be isolated from blood using a
hydrophilic polysaccharide, such as Ficoll®. For instance, PBMCs may be isolated from blood using
Ficoll-Paque® (a commercially-available density medium) as disclosed in the Example.
Before they are cultured, the MCs may be exposed to a mesenchymal stem cell enrichment
cocktail. The cocktail preferably comprises antibodies that recognise CD3, CD14, CD19, CD38,
CD66b (which are present on unwanted cells) and a component of red blood cells. Such a cocktail
cross links unwanted cells with red blood cells forming immunorosettes which may be removed from
the wanted MCs. A preferred cocktail is RosetteSep®.
Conditions suitable for inducing MCs to differentiate into mesenchymal cells (tissue mainly
derived from the mesoderm) are known in the art. For instance, suitable conditions are disclosed in
Capelli, C., et al. (Human platelet lysate allows expansion and clinical grade production of
mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts.
Bone Marrow Transplantation, 2007. 40: p. 785-791). These conditions may also be used to induce
MCs to differentiate into IMP cells described herein.
The method preferably comprises culturing MCs with plasma lysate to induce the MCs to
differentiate into IMP cells. Platelet lysate refers to the combination of natural growth factors
contained in platelets that has been released through lysing those platelets. Lysis can be accomplished
through chemical means (i.e. CaCl ), osmotic means (use of distilled H O) or through freezing/thawing
procedures. Platelet lysate can be derived from whole blood as described in U.S. Pat. No. 5,198,357.
Platelet lysate is preferably prepared as described in PCT/GB12/052911 (published as WO
2013/076507). The plasma lysate is preferably human plasma lysate.
In a preferred embodiment, step (a) of the method of the invention comprises culturing MCs in
a medium comprising platelet lysate for sufficient time to induce the MCs to differentiate into IMP
cells. The sufficient time is typically from about 15 to about 25 days, preferably about 22 days. The
medium preferably comprises about 20% or less platelet lysate by volume, such as about 15% or less
by volume or about 10% or less by volume. The medium preferably comprises from about 5% to about
% of platelet lysate by volume, such as from about 10% to about 15% by volume. The medium
preferably comprises about 10% of platelet lysate by volume.
In another preferred embodiment, step (a) of the method of the invention comprises exposing
MCs to a mesenchymal enrichment cocktail and then culturing the MCs in a medium comprising
platelet lysate for sufficient time to induce the MCs to differentiate into IMP cells. The sufficient time
is typically from about 15 to about 25 days, preferably about 22 days.
In step (a), the medium is preferably Minimum Essential Medium (MEM). MEM is
commercially available from various sources including Sigma-Aldrich. The medium preferably further
comprises one or more of heparin, L-glutamine and penicillin/streptavidin (P/S). The L-glutamine may
be replaced with GlutaMAX® (which is commercially-available from Life Technologies).
As discussed above, some of the IMP cells described herein express detectable levels of
CXCR4. Expression of CXCR4 is cytokine ‐dependent and is increased when cells are exposed to stem
cell factor (SCF), interleukin-6 (IL ‐6), Flt ‐3 ligand, hepatocyte growth factor (HGF) and IL ‐3. The
medium may comprise one or more of (i) SCF, (ii) IL ‐6, (iii) Flt ‐3 ligand, (iv) hepatocyte growth factor
and (v) IL ‐3, such as (i); (ii); (iii); (iv); (v); (i) and (ii); (i) and (iii); (i) and (iv); (i) and (v); (ii) and
(iii); (ii) and (iv); (ii) and (v); (iii) and (iv); (iii) and (v); (iv) and (v); (i), (ii) and (iii); (i), (ii) and (iv);
(i), (ii) and (v); (i), (iii) and (iv); (i), (iii) and (v); (i), (iv) and (v); (ii), (iii) and (iv); (ii), (iii) and (v);
(ii), (iv) and (v); (iii), (iv) and (v); or (i), (ii), (iii), (iv) and (v). Any of (i) to (v) may be present at from
about from about 10 to about about 150 ng/ml.
Step (a) preferably comprises culturing the MCs under conditions which allow the IMP cells to
adhere. Suitable conditions are discussed in more detail above.
In step (a), the MCs are preferably cultured under low oxygen conditions. The MCs are
preferably cultured at less than about 20% oxygen (O ), such as less than about 19%, less than about
18%, less than about 17%, less than about 16%, less than about 15%, less than about 14%, less than
about 13%, less than about 12%, less than about 11%, less than about 10%, less than about 9%, less
than about 8%, less than about 7%, less than about 6%, less than about 5%, less than about 4%, less
than about 3%, less than about 2% or less than about 1% oxygen (O ). The MCs are preferably
cultured at from about 0% to about 19% O , such as from about 1% to about 15% O , from about 2% to
about 10% O or from about 5% to about 8% O . The MCs are most preferably cultured at about 0%
2 2
O . The figures for % oxygen (or % O ) quoted above relate to % by volume of oxygen in the gas
supplied to the cells during culture, for instance by the cell incubator. It is possible that some oxygen
may leak into the incubator or enter when the door is opened.
In step (a), the MCs are most preferably cultured in the presence of platelet lysate and under
low oxygen conditions. This combination mimics the natural conditions in the damaged tissue and so
result in healthier and more therapeutically potent cells. Conventional cell culture is performed in 20%
or 21% oxygen (approximately the atmospheric content) but there is no place in the human body that
has this oxygen level. The epithelial cells in the lungs would “see” this oxygen level, but once the
oxygen is dissolved and leaves the lungs, it decreases to around 17%. From there, it decreases even
further to about 1-2% in the majority of the tissues, but being as low as 0.1% in avascular tissues such
as the cartilage in the joints.
In step (b), the method further comprises harvesting and culturing IMP cells which have the
necessary marker expression pattern as discussed above. The IMP cells having the necessary marker
expression pattern may be harvested using any antibody-based technique, including fluorescent
activated cell sorting (FACS) and magnetic bead separation. FACS is preferred. HT-FACS is more
preferred.
Any of the methods for culturing IMP cells disclosed in relation to step (a) equally apply to step
(b). In particular, the cells are cultured in step (b) in the presence of platelet lysate and under low
oxygen conditions as discussed above in relation to step (a).
As will be clear from the discussion above, the method of the invention is carried out in
clinically relevant conditions, i.e. in the absence of trace amounts of endotoxins and other
environmental contaminants, such as lipopolysaccharides, lipopeptides and peptidoglycans, etc. This
makes the IMP cells described herein particularly suitable for administration to patients.
The MCs are preferably obtained from a patient or an allogeneic donor. The invention also
provides a method for producing a population of the invention that is suitable for administration to a
patient, wherein the method comprises culturing MCs obtained from the patient under conditions which
induce the MCs to differentiate into IMP cells and (b) harvesting and culturing those progenitor cells
which have an expression pattern as defined above and thereby producing a population of the invention
that is suitable for administration to the patient. The population will be autologous with the patient and
therefore will not be rejected upon implantation. The invention also provides a population of the
invention that is suitable for administration to a patient and is produced in this manner.
Alternatively, the invention provides a method for producing a population of the invention that
is suitable for administration to a patient, wherein the method comprises culturing MCs obtained from a
different patient that is immunologically compatible with the patient into which the cells will be
administered under conditions which induce the MCs to differentiate into IMP cells and (b) harvesting
and culturing those IMP cells which have an expression pattern as defined above and thereby producing
a population of the invention that is suitable for administration to the patient. The population will be
allogeneic with the patient and therefore will reduce the chance of rejection upon implantation. The
invention also provides a population of the invention that is suitable for administration to a patient and
is produced in this manner.
Medicaments, methods and therapeutic use
The IMP cells described herein may be used in a method of therapy of the human or animal
body. Thus described herein is an IMP cell described herein or a population of the invention for use in
a method of treatment of the human or animal body by therapy. In particular, the invention concerns
using the IMP cells described herein or a population of the invention to repair a damaged tissue in a
patient. Also described is using the IMP cells described herein or a population of the invention to treat
a cardiac, bone, cartilage, tendon, ligament, liver, kidney or lung injury or disease in the patient.
Described herein is a method of repairing a damaged tissue in a patient, comprising
administering to the patient a population of the invention, wherein the population comprises a
therapeutically effective number of cells, and thereby treating the damaged tissue in the patient. Also
described is a population of the invention for use in repairing a damaged tissue in the patient. The
invention also provides use of a population of the invention in the manufacture of a medicament for
repairing a damaged tissue in a patient.
The tissue is preferably derived from the mesoderm. The tissue is more preferably cardiac,
bone, cartilage, tendon, ligament, liver, kidney or lung tissue.
The damage to the tissue may be caused by injury or disease. The injury or disease is
preferably a cardiac, bone, cartilage, tendon, ligament, liver, kidney or lung injury or disease in a
patient. Described herein is a method of treating a cardiac, bone, cartilage, tendon, ligament, liver,
kidney or lung injury or disease in a patient, comprising administering to the patient a population of the
invention, wherein the population comprises a therapeutically effective number of cells, and thereby
treating the injury or disease in the patient. Also described is a population of the invention for use in
treating a cardiac, bone, cartilage, tendon, ligament, liver, kidney or lung injury or disease in a patient.
The invention also provides use of a population of the invention in the manufacture of a medicament
for treating a cardiac, bone, cartilage, tendon, ligament, liver, kidney or lung injury or disease in a
patient.
The cardiac injury or disease is preferably selected from myocardial infarct (MI), left
ventricular hypertrophy, right ventricular hypertrophy, emboli, heart failure, congenital heart deficit,
heart valve disease, arrhythmia and myocarditis.
MI increases the levels of VEGF and EPO released by the myocardium. Furthermore, MI is
associated with an inflammatory reaction and infarcted tissue also releases macrophage migration
inhibitory factor (MIF), interleukin (IL ‐6) and KC/Gro ‐alpha. CCL7 (previously known as MCP3),
CXCL1, CXCL2 are significantly upregulated in the heart following myocardial infarct (MI) and might
be implicated in regulating engraftment and homing of MSCs to infarcted myocardium.
In a myocardial infarct mice model, IL ‐8 was shown to highly up ‐regulate gene expression
primarily in the first 2 days post ‐MI. Remarkably, the increased IL ‐8 expression was located
predominantly in the infarcted area and the border zone, and only to a far lesser degree in the spared
myocardium. By activating CXCR2, MIF displays chemokine ‐like functions and acts as a major
regulator of inflammatory cell recruitment and atherogenesis.
The bone disease or injury is preferably selected from fracture, Salter-Harris fracture,
greenstick fracture, bone spur, craniosynostosis, Coffin-Lowry syndrome, fibrodysplasia ossificans
progressive, fibrous dysplasia, Fong Disease (or Nail-patella syndrome), hypophosphatasia, Klippel-
Feil syndrome, Metabolic Bone Disease, Nail-patella syndrome, osteoarthritis, osteitis deformans (or
Paget's disease of bone), osteitis fibrosa cystica (or Osteitis fibrosa or Von Recklinghausen's disease of
bone), osteitis pubis, condensing osteitis (or osteitis condensans), osteitis condensans ilii,
osteochondritis dissecans, osteogenesis imperfecta, osteomalacia, osteomyelitis, osteopenia,
osteopetrosis, osteoporosis, osteonecrosis, porotic hyperostosis, primary hyperparathyroidism, renal
osteodystrophy, bone cancer, a bone lesion associated with metastatic cancer, Gorham Stout disease,
primary hyperparathyroidism, periodontal disease, and aseptic loosening of joint replacements. The
bone cancer can be Ewing sarcoma, multiple myeloma, osteosarcoma (giant tumour of the bone),
osteochondroma or osteoclastoma. The metastatic cancer that results in a bone lesion can be breast
cancer, prostate cancer, kidney cancer, lung cancer and/or adult T-cell leukemia.
If the damaged tissue is cardiac tissue or bone tissue, the IMP cells in the population preferably
express detectable levels of CD29, CD44, CD73, CD90, CD105, CD271, CXCR1, CXCR2 and
CXCR4 and do not express detectable levels of CD14, CD34 and CD45. If the damaged tissue is bone
tissue, the IMP cells in the population more preferably express detectable levels of CD29, CD44,
CD73, CD90, CD105, CD271, TGF-beta 3, bone morphogenetic protein-6 (BMP-6), SOX-9, Collagen-
2, CD117 (c-kit), chemokine (C-C motif) ligand 12 (CCL12), CCL7, interleukin-8 (IL-8), platelet-
derived growth factor-A (PDGF-A), PDGF-B, PDGF-C, PDGF-D, macrophage migration inhibitory
factor (MIF), IGF-1, hepatocyte growth factor (HGF), PDGF-Rα, PDGF-Rβ, CXCR4, C-C chemokine
receptor type 1 (CCR1), IGF-1 receptor (IGF-1R), hepatocyte growth factor receptor (HGFR),
CXCL12 and NFkappaB and do not express detectable levels of CD14, CD34 and CD45.
The disease or disorder may be periodontal disease, endometriosis or meniscal tears.
In all instances, the IMP cells described herein are preferably derived from the patient or an
allogeneic donor. Deriving the IMP cells from the patient should ensure that the IMP cells are
themselves not rejected by the patient’s immune system. Any difference between the donor and
recipient will ultimately cause clearance of the IMP cells, but not before they have repaired at least a
part of the damaged tissue.
The invention concerns administering to the patient a therapeutically effective number of IMP
cells of the invention to the patient. A therapeutically effective number is a number which ameliorates
one or more symptoms of the damage, disease or injury. A therapeutically effective number is
preferably a number which repairs the damaged tissue or treats the disease or injury. Suitable numbers
are discussed in more detail below.
The IMP cells described herein may be administered to any suitable patient. The patient is
generally a human patient. The patient may be any of the animals or mammals mentioned above with
reference to the source of the IMP cells.
The patient may be an infant, a juvenile or an adult. The patient may be known to have a
damaged tissue or is suspected of having a damaged tissue. The patient may be susceptible to, or at risk
from, the relevant disease or injury. For instance, the patient may be genetically predisposed to heart
failure.
The invention may be used in combination with other means of, and substances for, repairing
damaged tissue or providing pain relief. In some cases, the IMP cells described herein may be
administered simultaneously, sequentially or separately with other substances which are intended for
repairing the damaged tissue or for providing pain relief. The IMP cells may be used in combination
with existing treatments for damaged tissue and may, for example, be simply mixed with such
treatments. Thus the invention may be used to increase the efficacy of existing treatments of damaged
tissue.
Described herein is the use of IMP cells loaded or transfected with a therapeutic and/or
diagnostic agent. A therapeutic agent may help to repair the damaged tissue. A diagnostic agent, such
as a fluorescent molecule, may help to identify the location of the IMP cells in the patient. The IMP
cells may be loaded or transfected using any method known in the art. The loading of IMP cells may
be performed in vitro or ex vivo. In each case, the IMP cells may simply be in contact with the agent in
culture. Alternatively, the IMP cells may be loaded with an agent using delivery vehicle, such as
liposomes. Such vehicles are known in the art.
The transfection of IMP cells may be performed in vitro or ex vivo. Alternatively, stable
transfection may be perfomed at the MC stage allowing IMP cells expressing the transgene to be
differentiated from them. The IMP cells are transfected with a nucleic acid encoding the agent. For
instance, viral particles or other vectors encoding the agent may be employed. Methods for doing this
are known in the art.
The nucleic acid gives rise to expression of the agent in the IMP cells. The nucleic acid
molecule will preferably comprise a promoter which is operably linked to the sequences encoding the
agent and which is active in the IMP cells or which can be induced in the IMP cells.
In a particularly preferred embodiment, the nucleic acid encoding the agent may be delivered
via a viral particle. The viral particle may comprise a targeting molecule to ensure efficient
transfection. The targeting molecule will typically be provided wholly or partly on the surface of the
virus in order for the molecule to be able to target the virus to the IMP cells.
Any suitable virus may be used in such embodiments. The virus may, for example, be a
retrovirus, a lentivirus, an adenovirus, an adeno-associated virus, a vaccinia virus or a herpes simplex
virus. In a particularly preferred embodiment the virus may be a lentivirus. The lentivirus may be a
modified HIV virus suitable for use in delivering genes. The lentivirus may be a SIV, FIV, or equine
infectious anemia virus (EQIA) based vector. The virus may be a moloney murine leukaemia virus
(MMLV). The viruses used in the invention are preferably replication deficient.
Viral particles do not have to be used. Any vector capable of transfecting the IMP cells
described herein may be used, such as conventional plasmid DNA or RNA transfection.
Uptake of nucleic acid constructs may be enhanced by several known transfection techniques,
for example those including the use of transfection agents. Examples of these agents includes cationic
agents, for example, calcium phosphate and DEAE-Dextran and lipofectants, for example,
lipofectAmine, fugene and transfectam.
The cell may be loaded or tranfected under suitable conditions. The cell and agent or vector
may, for example, be contacted for between five minutes and ten days, preferably from an hour to five
days, more preferably from five hours to two days and even more preferably from twelve hours to one
day.
Also described are IMP cells which have been loaded or transfected with an agent as discussed
above. Such IMP cells may be used in the therapeutic embodiments described herein.
In some embodiments, MCs may be recovered from a patient, converted into IMP cells using
the invention, loaded or transfected in vitro and then returned to the same patient. In such instances, the
IMP cells employed as described herein, will be autologous cells and fully matched with the patient. In
a preferred case, the cells employed as described herein are recovered from a patient and utilised ex
vivo and subsequently returned to the same patient.
Pharmaceutical compositions and administration
The invention additionally provides a pharmaceutical composition comprising an IMP cell
described herein or a population of the invention in combination with a pharmaceutically acceptable
carrier or diluent, (ii) one or more lipsomes and/or (iii) one or more microbubbles. The composition
may comprise (i); (ii); (iii); (i) and (ii); (i) and (iii); (ii) and (iii); or (i), (ii) and (iii). The IMP cell or
population are preferably contained with the one or more liposomes and/or one or more microbubbles.
Any number of liposomes and/or microbubbles may be present. Any of the numbers discussed above
with reference to the population of the invention are equally application to the lipsomes and/or
microbubbles. A lipsome or microbubble may contain one IMP cell or more than one IMP cell.
The composition may comprise any of the IMP cells or populations mentioned herein and, in
some embodiments, the nucleic acid molecules, vectors, or viruses described herein. Described herein
is a method of repairing a damaged tissue in a patient comprising administering to the patient an
effective amount of a pharmaceutical composition of the invention. Any of the therapeutic
embodiments discussed above equally apply to this embodiment.
The various compositions of the invention may be formulated using any suitable method.
Formulation of cells with standard pharmaceutically acceptable carriers and/or excipients may be
carried out using routine methods in the pharmaceutical art. The exact nature of a formulation will
depend upon several factors including the cells to be administered and the desired route of
administration. Suitable types of formulation are fully described in Remington's Pharmaceutical
Sciences, 19 Edition, Mack Publishing Company, Eastern Pennsylvania, USA.
The cells may be administered by any route. Suitable routes include, but are not limited to,
intravenous, intramuscular, intraperitoneal or other appropriate administration routes. If the damaged
tissue is cardiac tissue, the cells may be administered via an endomyocardial, epimyocardial,
intraventicular, intracoronary, retrograde coronary sinus, intra-arterial, intra-pericardial or intravenous
route. If the damaged tissue is bone, the cells may be administered via an intraosseous route or to the
site of the injury, such as a fracture, or disease. If the damaged tissue is cartilage, tendon, ligament,
liver, kidney or lung tissue, the cells may be administered directly into the tissue. If the damaged tissue
is lung tissue, the cells may be introduced via an intra-pulmonary route. If the damaged tissue is liver
or kidney, the cells may be introduced via an intra-peritoneal route. The cells are preferably
administered intravenously.
Compositions may be prepared together with a physiologically acceptable carrier or diluent.
Typically, such compositions are prepared as liquid suspensions of cells. The cells may be mixed with
an excipient which is pharmaceutically acceptable and compatible with the active ingredient. Suitable
excipients are, for example, water, saline, dextrose, glycerol, of the like and combinations thereof.
In addition, if desired, the pharmaceutical compositions of the invention may contain minor
amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or
adjuvants which enhance effectiveness. The composition preferably comprises human serum albumin.
One suitable carrier or diluents is Plasma-Lyte A®. This is a sterile, nonpyrogenic isotonic
solution for intravenous administration. Each 100 mL contains 526 mg of Sodium Chloride, USP
(NaCl); 502 mg of Sodium Gluconate (C6H11NaO7); 368 mg of Sodium Acetate Trihydrate, USP
(C2H3NaO2•3H2O); 37 mg of Potassium Chloride, USP (KCl); and 30 mg of Magnesium Chloride,
USP (MgCl2•6H2O). It contains no antimicrobial agents. The pH is adjusted with sodium hydroxide.
The pH is 7.4 (6.5 to 8.0).
The IMP cells may be contained within one or more liposomes and/or one or more
microbubbles. Suitable liposomes are known in the art. Suitable liposomes are disclosed in, for
example, Akbarzadeh et al. Nanoscale Research Letters 2013, 8:102 and Meghana et al. International
Journal Of Pharmaceutical And Chemical Sciences, 2012, 1(1): 1-10. Suitable lipids for use in forming
liposomes are discussed below with reference to microbubbles.
Microbubbles, their formation and biomedical uses are known in the art (e.g. Sirsi and Borden,
Bubble Sci Eng Technol. Nov 2009; 1(1-2): 3–17). Microbubbles are bubbles smaller than one
millimetre in diameter and larger than one micrometre in diameter. The microbubble used in the
present invention is preferably 8µm or less in diameter, such as 7µm or less in diameter, 6µm or less in
diameter, 5µm or less in diameter, 4µm or less in diameter, 3µm or less in diameter or 2µm or less in
diameter.
The microbubble may be formed from any substance. The general composition of a
microbubble is a gas core stabilised by a shell. The gas core may comprise air or a heavy gas, such as
perfluorocarbon, nitrogen or perflouropropane. Heavy gases are less water soluble and so are less
likely to leak out from the microbubble leading to microbubble dissolution. Microbubbles with heavy
gas cores typically last longer in circulation.
The shell may be formed from any material. The shell material preferably comprises a protein,
a surfactant, a lipid, a polymer or a mixture thereof.
Suitable proteins, include but are not limited to, albumin, lysozyme and avidin. Proteins within
the shell may be chemically-crosslinked, for instance by cysteine-cysteine linkage. Other crosslinkages
are known in the art.
Suitable surfactants include, but are not limited to, sorbitan monopalmitate (such as SPAN-40),
polysorbate detergents (such as TWEEN-40), mixtures of SPAN-40 and TWEEN-40 and sucrose
stearate (mono- and di-ester).
Suitable polymers include, but are not limited to, alginate polymers, double ester polymers of
ethylidene, the copolymer poly(D,L-lactide-co-glycolide) (PLGA), poly(vinyl alcohol) (PVA), the
copolymer polyperfluorooctyloxycaronyl-poly(lactic acid) (PLA-PFO) and other block copolymers.
Block copolymers are polymeric materials in which two or more monomer sub-units that are
polymerized together to create a single polymer chain. Block copolymers typically have properties that
are contributed by each monomer sub-unit. However, a block copolymer may have unique properties
that polymers formed from the individual sub-units do not possess. Block copolymers can be
engineered such that one of the monomer sub-units is hydrophobic (i.e. lipophilic), whilst the other sub-
unit(s) are hydrophilic whilst in aqueous media. In this case, the block copolymer may possess
amphiphilic properties and may form a structure that mimics a biological membrane. The block
copolymer may be a diblock (consisting of two monomer sub-units), but may also be constructed from
more than two monomer sub-units to form more complex arrangements that behave as amphipiles.
The copolymer may be a triblock, tetrablock or pentablock copolymer. Block copolymers may also be
constructed from sub-units that are not classed as lipid sub-materials; for example a hydrophobic
polymer may be made from siloxane or other non-hydrocarbon based monomers. The hydrophilic sub-
section of block copolymer can also possess low protein binding properties, which allows the creation
of a membrane that is highly resistant when exposed to raw biological samples. This head group unit
may also be derived from non-classical lipid head-groups.
Any lipid material that forms a microbubble may be used. The lipid composition is chosen such
that the microbubble has the required properties, such surface charge, packing density or mechanical
properties. The lipid composition can comprise one or more different lipids. For instance, the lipid
composition can contain up to 100 lipids. The lipid composition preferably contains 1 to 10 lipids. The
lipid composition may comprise naturally-occurring lipids and/or artificial lipids.
The lipid typically comprises a head group, an interfacial moiety and two hydrophobic tail
groups which may be the same or different. Suitable head groups include, but are not limited to, neutral
head groups, such as diacylglycerides (DG) and ceramides (CM); zwitterionic head groups, such as
phosphatidylcholine (PC), phosphatidylethanolamine (PE) and sphingomyelin (SM); negatively
charged head groups, such as phosphatidylglycerol (PG); phosphatidylserine (PS), phosphatidylinositol
(PI), phosphatic acid (PA) and cardiolipin (CA); and positively charged headgroups, such as
trimethylammonium-Propane (TAP). Suitable interfacial moieties include, but are not limited to,
naturally-occurring interfacial moieties, such as glycerol-based or ceramide-based moieties. Suitable
hydrophobic tail groups include, but are not limited to, saturated hydrocarbon chains, such as lauric
acid (n-Dodecanolic acid), myristic acid (n-Tetradecononic acid), palmitic acid (n-Hexadecanoic acid),
stearic acid (n-Octadecanoic) and arachidic (n-Eicosanoic); unsaturated hydrocarbon chains, such as
oleic acid (cisOctadecanoic); and branched hydrocarbon chains, such as phytanoyl. The length of
the chain and the position and number of the double bonds in the unsaturated hydrocarbon chains can
vary. The length of the chains and the position and number of the branches, such as methyl groups, in
the branched hydrocarbon chains can vary. The hydrophobic tail groups can be linked to the interfacial
moiety as an ether or an ester.
The lipids can also be chemically-modified. The head group or the tail group of the lipids may
be chemically-modified. Suitable lipids whose head groups have been chemically-modified include,
but are not limited to, PEG-modified lipids, such as 1,2-Diacyl-sn-GlyceroPhosphoethanolamine-N -
[Methoxy(Polyethylene glycol)-2000]; functionalised PEG Lipids, such as 1,2-Distearoyl-sn-Glycero-3
Phosphoethanolamine-N-[Biotinyl(Polyethylene Glycol)2000]; and lipids modified for conjugation,
such as 1,2-Dioleoyl-sn-GlyceroPhosphoethanolamine-N-(succinyl) and 1,2-Dipalmitoyl-sn-
GlyceroPhosphoethanolamine-N-(Biotinyl). Suitable lipids whose tail groups have been chemically-
modified include, but are not limited to, polymerisable lipids, such as 1,2-bis(10,12-tricosadiynoyl)-sn-
GlyceroPhosphocholine; fluorinated lipids, such as 1-Palmitoyl(16-Fluoropalmitoyl)-sn-Glycero-
3-Phosphocholine; deuterated lipids, such as 1,2-Dipalmitoyl-D62-sn-GlyceroPhosphocholine; and
ether linked lipids, such as 1,2-Di-O-phytanyl-sn-GlyceroPhosphocholine. The lipids may be
chemically-modified or functionalised to facilitate coupling of the ligands, receptors ro antibodies as
discussed above.
The lipid composition may comprise one or more additives that will affect the properties of the
microbubble. Suitable additives include, but are not limited to, fatty acids, such as palmitic acid,
myristic acid and oleic acid; fatty alcohols, such as palmitic alcohol, myristic alcohol and oleic alcohol;
sterols, such as cholesterol, ergosterol, lanosterol, sitosterol and stigmasterol; lysophospholipids, such
as 1-AcylHydroxy-sn- GlyceroPhosphocholine; and ceramides.
The microbubble shell is preferably formed from a phospholipid. Suitable phospholipids are
known in the art.
There are several commercially available lipid shell microbubble formulations such as Definity
(Lantheus Medical Imaging) and Sonovue® (Bracco Diagnostics).
The microbubble may also be formed from a polymer-surfactant hybrid that involves forming
polyelectrolyte multilayer (PEM) shells on a preformed microbubble. The preformed microbubble is
coated with a charged surfactant or protein layer, which serves as a substrate for PEM deposition. The
layer-by-layer assembly technique is used to sequentially adsorb oppositely charged polyions to the
microbubble shell. For instance, PEM can be deposited onto microbubbles using poly(allylamine
hydrochloride) (PAH) and poly(styrene sulfonate) (PSS) for the polyion pair. PEM microbubbles with
phospholipid containing the cationic headgroup trimethylammonium propane (TAP) as the underlying
shell and DNA and poly(L-lysine) (PLL) as the polyion pair have also been developed.
The microbubble is typically formed by providing an interface between a gas and a
microbubble shell material. Any of the materials discussed above may be used. Some materials, such
as phospholipids, spontaneously form microbubbles. Phospholipids self assemble into a microbubble.
Other materials require sonication of the interface, i.e. the application of sound energy or sonic waves
to the interface. Ultrasonic waves are typically used. Suitable methods are known in the art for
sonication.
The microbubble may be loaded with the IMP cells after formation of the microbubble or
during formation of the microbubble.
The IMP cells are administered in a manner compatible with the dosage formulation and in
such amount will be therapeutically effective. The quantity to be administered depends on the subject
to be treated, capacity of the subject’s immune system and the degree repair desired. Precise amounts
of IMP cells required to be administered may depend on the judgement of the practitioner and may be
peculiar to each subject.
Any suitable number of cells may be administered to a subject. For example, at least, or about,
6 6 6 6 6 6
0.2 x 10 , 0.25 x 10 , 0.5 x 10 , 1.5 x 10 , 4.0 x 10 or 5.0 x 10 cells per kg of patient may
6 7 8 9
administered. For example, at least, or about, 10 , 10 , 10 , 10 , 10 cells may be administered. As a
to 10 , preferably from
guide, the number of cells described herein to be administered may be from 10
6 8 8
to 10 . Typically, up to 2 x 10 IMP cells are administered to each patient. Any of the specific
numbers discussed above with reference to the populations of the invention may be administered. In
such cases where cells are administered or present, culture medium may be present to facilitate the
survival of the cells. In some cases the cells described herein may be provided in frozen aliquots and
substances such as DMSO may be present to facilitate survival during freezing. Such frozen cells will
typically be thawed and then placed in a buffer or medium either for maintenance or for administration.
Hybrid composition
One or more IMP cells described herein may form part of a hybrid composition as disclosed in
the UK Application being filed concurrently with this application (CTL Ref: FIBRE1) and are
preferably administered to a patient as part of such a composition. In particular, described herein is a
hybrid composition, which comprises:
(a) one or more biocompatible fibres;
(b) one or more IMP cells described herein; and
(c) one or more biocompatible components which (i) attach the one or more therapeutic cells to
the one or more fibres and/or embed the one or more therapeutic cells and the one or more fibres and/or
(ii) are capable of attaching the composition to a tissue.
The hybrid composition described herein comprises one or more biocompatible fibres. A fibre
is biocompatible if it does not cause any adverse reactions or side effects when contacted with a
damaged tissue.
Any number of biocompatible fibres may be present in the composition. The composition may
comprise only one fibre. The composition typically comprises more than one fibre, such at least 2, at
least 5, at least 10, at least 20, at least 30, at least 40, at least 50, at least 100, at least 200, at least 500
fibres, at least 1000 fibres or even more fibres.
Suitable biocompatible fibres are known in the art. The one or more biocompatible fibres may
be natural or synthetic. Preferred biocompatible fibres include, but are not limited to, cellulose fibres,
collagen fibres, collagen-glycosaminoglycan fibres, gelatin fibres, silk fibroin fibres, one or more fibrin
fibres, chitosan fibres, starch fibres, alginate fibres, hyaluronan fibres, poloaxmer fibres or a
combination thereof. The glycosaminoglycan is preferably chondroitin. The cellulose is preferably
carboxymethylcellulose, hydroxypropylmethylcellulose or methylcellulose. The poloaxmer is
preferably pluronic acid, optionally Pluronic F-127.
If more than one fibre is present in the composition, the population of fibres may be
homogenous. In other words, all of the fibres in the population may be the same type of fibre, e.g.
cellulose fibres. Alternatively, the population of fibres may be heterogeneous. In other words, the
population of fibres may contain different types of fibre, such cellulose fibres and collagen fibres.
The one or more fibres may be any length. The one or more fibres are preferably
approximately the same length as the depth of the damage in the tissue which is to be treated using the
composition. The length of one or more fibres is preferably designed such that the composition can
penetrate a damaged tissue to a prescribed depth. The one or more fibres may be any length. The
lower limit of the length of the one or more fibres is typically determined by the diameter of the one or
more therapeutic cells. Suitable lengths include, but are not limited to, at least 1µm in length, at least
10µm in length, at least 100µm in length, at least 500µm in length, at least 1mm in length, at least
10mm (1cm) in length, at least 100mm (10cm) in length, at least 500mm (50cm) in length or at least
1000mm (100cm or 1m) in length. The one or more fibres may be even longer. For instance, the one
or more fibres may be up to 5m or 10m in length, for instance if being used to repair damage along the
human intestinal tract, or even longer if being used in larger animals, such as horses. The length of the
one or more fibres is typically determined by their intended use and/or their ability to be manipulated,
for instance by a surgeon, by a robot or via some other means, such as magnetically.
The one or more fibres may be charged. The one or more fibres are preferably positively-
charged. The one or more fibres are preferably negatively-charged.
The one or more fibres may be magnetic. The one or more fibres may be modified to include
one or more magnetic atoms or groups. This allows magnetic targeting of the composition. The
magnetic atoms or groups may be paramagnetic or superparamagnetic. Suitable atoms or groups
include, but are not limited to, gold atoms, iron atoms, cobalt atoms, nickel atoms and a metal chelating
groups, such as nitrilotriacetic acid, containing any of these atoms. The metal chelating group may, for
instance, comprise a group selected from -C(=O)O-, -C-O-C-, -C(=O), -NH-, -C(=O)-NH, -C(=O)-
CH -I, -S(=O) - and -S-.
The composition also comprises one or more biocompatible components. The one or more
biocompatible components (i) attach the one or more therapeutic cells to the one or more fibres and/or
embed the one or more therapeutic cells and the one or more fibres and/or (ii) are capable of attaching
the composition to a tissue. The one or more biocompatible components may (a) attach the one or more
therapeutic cells to the one or more fibres, (b) embed the one or more therapeutic cells and the one or
more fibres, (c) be capable of attaching the composition to a tissue, (d) attach the one or more
therapeutic cells to the one or more fibres and embed the one or more therapeutic cells and the one or
more fibres, (e) attach the one or more therapeutic cells to the one or more fibres and be capable of
attaching the composition to a tissue, (f) embed the one or more therapeutic cells and the one or more
fibres and be capable of attaching the composition to a tissue or (g) attach the one or more therapeutic
cells to the one or more fibres, embed the one or more therapeutic cells and the one or more fibres and
be capable of attaching the composition to a tissue.
A component is biocompatible if it does not cause any adverse reactions or side effects when
contacted with a damaged tissue.
Any number of biocompatible components may be present in the composition. The
composition typically comprises only one component or two components. The composition may
comprise more than two components, such as at least 3, at least 5, at least 10, at least 20, at least 30, at
least 40, at least 50 components or even more components.
The one or more biocompatible components preferably comprise a biocompatible adhesive
which attaches the one or more therapeutic cells to the one or more fibres. The biocompatible adhesive
may attach the one or more therapeutic cells (a) on the surface of the one or more fibres, (b) within the
one or more fibres or (c) both on the surface of and within the one or more fibres.
The biocompatible adhesive may be natural or synthetic. Suitable biocompatible adhesives are
known in the art. Suitable adhesives include, but are not limited to, fibrin, fibrin gel, integrin, integrin
gel, cadherin and cadherin gel.
The one or more biocompatible components preferably comprise a biocompatible gel which
embeds the one or more therapeutic cells and the one or more fibres. Suitable biocompatible gels are
known in the art. The biocompatible gel may be natural or synthetic. Preferred biocompatible gels
include, but are not limited to, a cellulose gel, a collagen gel, a gelatin gel, a fibrin gel, a chitosan gel, a
starch gel, an alginate gel, a hyaluronan gel, an agarose gel, a poloaxmer gel or a combination thereof.
The cellulose gel may be formed from any of the celluloses discussed above. The cellulose
polymer concentration is preferably from about 1.5% (w/w) to about 4.0% (w/w), such as from about
2.0% (w/w) to about 3.0% (w/w). The cellulose polymer preferably has a molecular weight of from
about 450,000 to about 4,000,000, such as from about 500,000 to about 3,500,000, from about 500,000
to about 3,000,000 or from about 750,000 to about 2,500,000 or from about 1000,000 to about
2,000,000.
The poloaxmer gel is preferably a pluronic acid gel, optionally a Pluronic F-127 gel.
The adhesive and/or gel preferably has a viscosity in the range of 1000 to 500,000 mPa•s (cps)
at room temperature, such as from about 1500 to about 450,000 mPa•s at room temperature, from about
2000 to about 400,000 mPa•s at room temperature, from about 2500 to about 350,000 mPa•s at room
temperature, from about 5000 to about 300,000 mPa•s at room temperature, from about 10,000 to about
250,000 mPa•s at room temperature, from about 50,000 to about 200,000 mPa•s at room temperature or
from about 50,000 to about 150,000 mPa•s at room temperature.
Viscosity is a measure of the resistance of the adhesive and/or gel to being deformed by either
shear stress or tensile stress. Viscosity can be measured using any method known in the art. Suitable
methods include, but are not limited to, using a viscometer or a rheometer.
Room temperature is typically from about 18 °C to about 25 °C, such as from about 19 °C to
about 24 °C or from about 20 °C to about 23 °C or from about 21 °C to about 22 °C. Room
temperature is preferably any of 18 °C, 19 °C, 20 °C, 21 °C, 22 °C, 23 °C, 24 °C and 25 °C. Viscosity
is most preferably measured at 25 °C.
The one or more biocompatible components preferably comprises a biocompatible adhesive
which attaches the one or more therapeutic cells to the one or more fibres and a biocompatible gel
which embeds the one or more therapeutic cells and the one or more fibres. For instance, the
composition may comprise a fibrin gel which attaches the one or more therapeutic cells to the one or
more fibres and a cellulose gel which embeds the one or more therapeutic cells and the one or more
fibres.
In any of the embodiments discussed above, the biocompatible adhesive and/or the
biocompatible gel preferably comprises platelet lysate. For instance, the adhesive and/or the gel may
be a platelet lystae gel. Platelet lysate refers to the combination of natural growth factors contained in
platelets that has been released through lysing those platelets. Lysis can be accomplished through
chemical means (i.e. CaCl ), osmotic means (use of distilled H O) or through freezing/thawing
procedures. Platelet lysate can be derived from whole blood as described in U.S. Pat. No. 5,198,357.
Platelet lysate is preferably prepared as described in PCT/GB12/052911 (published as WO
2013/076507). For instance, it may be prepared by subjecting a population of platelets to at least one
freeze-thaw cycle, wherein the freeze portion of each cycle is carried out at a temperature lower than or
equal to - 78 °C.
The adhesive and/or gel preferably comprises (a) platelet lysate, (b) at least one
pharmaceutically acceptable polymer and (c) at least one pharmaceutically acceptable positively
charged chemical species selected from the group consisting of lysine, arginine, histidine, aspartic acid,
glutamic acid, alanine, methionine, proline, serine, asparagine, cysteine, polyamino acids, protamine,
aminoguanidine, zinc ions and magnesium ions, wherein the composition is an aqueous gel having a
viscosity in the range of 1000 to 500,000 mPa•s (cps) at room temperature. The pharmaceutically
acceptable polymer is preferably cellulose or a poloaxmer. It may be any of the celluloses and
poloaxmers discussed above.
The platelet lysate is preferably human platelet lysate. Platelet lysate is discussed in more detail
above.
The hybrid composition may be contained within one or more liposomes or one or more
microbubbles. Such structures are known in the art.
The following Examples illustrate the invention.
Examples
Example 1 - Bone Marrow and Peripheral Blood Isolation & Expansion of IMP cells
A bone marrow sample was diluted with Hank Buffered Saline Solution and layered over
Ficoll-Paque for the isolation of mononuclear cells (MCs) by centrifugation. The MCs were then re-
suspended in Hank Buffered Saline Solution and counted using 0.4% trypan blue exclusion assay to
assess cellular viability. Cells were seeded in T25 flasks (in 5 ml of cell culture media, αMEM,
GlutaMAX, penicillin-streptomycin, platelet lysate, heparin), and incubated at 37°C, 5% CO2. On day
8 the media was changed. Cells were monitored daily for observation of IMP-like cells and, if present,
harvested using cell dissociating solution according to manufacturer’s instructions and sub-cultured in
the same media as above. Cells were cryopreserved in passage 2 in culture media supplemented with
% dimethyl sulfoxide to -80°C and stored in liquid nitrogen for later use.
Example 2 – HT-FACS analysis
High-throughput fluorescence activated cell sorting (HT-FACS) analysis is a high-throughput
screening platform which can rapidly characterize the cell surface phenotype of cells in suspension,
with over 370 cell surface markers currently in the panel. This platform has undergone extensive
validation and has been performed on many types of human tissues and cells. The panel consists of 375
human cell surface-specific antibodies arrayed in 96-well plates.
The aim was to determine the surface antigen expression profile of human IMPs described
herein and human MSCs obtained from Lonza®. The high-throughput-FACS (HT-FACS) platform
allows the screening of 375 surface antigens.
One vial of cryopreserved PB-MSCs (1x106 cells/ml) was seeded in a T75 cm2 flask containing
15 mL of CTL media (37°C, 5% CO2). Cells were grown until confluence of 80-90% changing the
media every 2-3 days. To passage the cells, the media was removed and cells were washed twice with
PBS. Cells were treated with 3 ml of Trypsin 0.25% until detached. Eight ml of media were added to
inactivate the trypsin and cells were collected by centrifugation at 400g for 5 min. Cells were re-
suspended in 5 ml of media and seeded in a T175 cm2 flask containing 30 mL of CTL media (37°C,
5% CO2). Between 8 to 10 T175 cm2 flasks at 80-90% confluence were required to harvest 20-30
million cells (at passage 4) for the HT-FACS screening. In order to obtain a sufficient number of flow
cytometry "events" per antibody, approximately 20 million viable cells is optimal. To collect the cells,
the media was removed and cells were washed twice with PBS. Cells were treated with 5 ml of Trypsin
0.25% until detached. Media was added (8 ml) to inactivate the trypsin and collect the cells. Cells were
centrifuged at 400g for 5 min. The cell pellets were re-suspended (single-cell suspension) in 5 ml total
of HBSS (Hank's Balanced Salt Solution minus calcium/magnesium, supplemented with 2mM EDTA
and 1% BSA). One aliquot of the sample (10 μl) was used to determine the total number of viable cells
by using exclusion dye (0.2% trypan blue).
100 μl of sample were loaded into each well (about 40,000 cells per well assuring the collection
of 10,000 to 20,000 events in the FACS). The samples were run in a BD FACSDiva upgraded with a
BD High Throughput Sampler (automated sampler). The analysis of flow cytometry data were
performed using FlowJo Software. The results were provided in plots, and an Excel spreadsheet
containing the percentage of positive cells and median fluorescence intensity (MFI) for each antibody.
Table 1 – Results of the HT-FACS analysis
# Marker Alternative name: % IMP %
Lonza®
1 BLTR-1 6.7 1.37
2 B2- 99.8 100
microglobuli
3 CA9 Carbonic anhydrase 9 5.22 0
4 CDH3 Cadherin-3/ P-Cadherin 2.93 0.475
CDH6 Cadherin-6 0.6 0.235
6 CDH11 Cadherin-11 61.6 0.88
7 CDw93 11.5 4.75
8 CDw198 CCR8 10.6 5.17
9 CDw199 CCR9 17.2 2.54
CDw210 Interleukin 10 receptor, alpha subunit (IL10RA) 10.8 0.622
11 CDw218a interleukin-18 receptor 1 (IL18R1) 0.384 0
12 CDw329 Sialic acid-binding Ig-like lectin 9 (Siglec 9) 0.182 0
13 CD1a 0.338 0.28
14 CD1b 0.766 0.745
CD1c 15.7 0.926
16 CD1d R3G1 2.7 0
17 CD2 LFA-2 0.292 0.526
18 CD3 0.158 0
19 CD3e 0.087 0
CD4 1.11 0.157
21 CD5 Leu-1 0.151 0.34
22 CD6 1.04 2.68
23 CD7 GP40/Leu-9 0.239 0.24
24 CD8 0.214 0
CD8b 4.34 0.705
26 CD9 BTCC-1 38.1 51.9
27 CD10 Neprilysin (NEP)/ common acute lymphoblastic 90.6 87.1
leukemia antigen (CALLA)
28 CD11a ITGAL, LFA-1 1.57 0
29 CD11b Integrin alpha M (ITGAM) 6.24 0
CD11c Integrin, alpha X (ITGAX) 1.8 0
31 CD13 Alanine aminopeptidase (ANPEP) 100 100
32 CD14 8.03 6.25
33 CD15 SSEA-1 0.137 0.474
34 CD16 Fc Receptor 10.1 3.73
CD16b Fc fragment of IgG, low affinity IIIb, receptor 0.331 0
(FCGR3B)
36 CD17 Lactosylceramide (LacCer) 20.9 0.462
37 CD18 Integrin beta-2 0.65 0
38 CD19 0.21 0
39 CD20 0.176 0
40 CD21 Complement receptor type 2 (Cr2)/ Epstein-Barr 0.66 0
virus receptor (EBV R)
41 CD22 BL-CAM/Siglec-2 0.596 0
42 CD23 Low affinity immunoglobulin epsilon Fc receptor 0.551 0.234
(FCER2)
43 CD24 0.987 4
44 CD25 Interleukin-2 receptor subunit alpha (IL2RA) 1.44 1.67
45 CD26 Dipeptidyl peptidase IV (DPP4) 21.3 6.33
46 CD27 Tumor necrosis factor receptor superfamily 0.409 0
member 7 (TNFRSF7)
47 CD28 0.643 0
48 CD29 Integrin beta-1 (ITGB1) 100 100
49 CD30 Tumor necrosis factor receptor superfamily 0.446 0
member 8 (TNFRSF8)
50 CD31 PECAM 1.29 0.214
51 CD32 Low affinity immunoglobulin gamma Fc region 0.698 3.46
receptor II-b
52 CD33 Siglec-3 1.25 0.372
53 CD34 0.287 0.885
54 CD35 Complement receptor type 1 (Cr1) 0.134 0
55 CD36 Platelet glycoprotein 4/Thrombospondin receptor 0.458 3.57
56 CD37 Tetraspanin-26 (TSPAN26) 0.0917 0.182
57 CD38 ADP-ribosyl cyclase 1 0.28 0
58 CD39 Ectonucleoside triphosphate diphosphohydrolase 0.126 21.8
NTPdase 1
59 CD40 Tumor necrosis factor receptor superfamily 0.132 3.12
member 5 (TNFRSF5)
60 CD41a 0.293 0
61 CD41b 0.075 0
62 CD42a Platelet glycoprotein IX 0.528 0.131
63 CD42b Platelet glycoprotein Ib alpha chain 7.29 0
64 CD43 Leukosialin 0.406 1.81
65 CD44 Epican 99.9 99.7
66 CD45 Receptor-type tyrosine-protein phosphatase C, 0.271 0
Leukocyte common antigen
67 CD45RA 5.18 2.99
68 CD45RB 0.283 0.671
69 CD45RO 0.57 0
70 CD46 Membrane cofactor protein, Trophoblast 78.1 22.5
leukocyte common antigen
71 CD47 Antigenic surface determinant protein OA3 92.3 99.9
72 CD48 SLAM F2 0.141 0.125
73 CD49a Integrin alpha-1 (ITGA1) 24 51.5
74 CD49b Integrin alpha-2 (ITGA2) 97.7 45.8
75 CD49c Integrin alpha-3 (ITGA3) 99.9 99.6
76 CD49d Integrin alpha-4 (ITGA4) 93.7 26
77 CD49e Integrin alpha-5 (ITGA5) 100 99.8
78 CD49f Integrin alpha-6 (ITGA6) 93.3 24.1
79 CD50 ICAM-3 0.244 0.8
80 CD51/CD61 92.7 68
81 CD52 CAMPATH-1 antigen 0.218 0.128
82 CD53 1.66 0.292
83 CD54 ICAM-1 23.1 23.7
84 CD55 Complement decay-accelerating factor 94.5 52.5
85 CD56 NCAM 3.05 4.71
86 CD57 Killer cell lectin-like receptor subfamily G 0.193 0
member 1
87 CD58 LFA-3 99.7 98.1
88 CD59 Protectin 100 100
89 CD60b 34 10.9
90 CD61 Integrin beta-3 ITGB3 81.8 56.7
91 CD62E E-Selectin Ligand 2.33 1.03
92 CD62L L-Selectin Ligand 0.432 0.151
93 CD62P P-Selectin Ligand 0.325 0.924
94 CD63 Lysosomal-associated membrane protein 3 99.1 95.8
(LAMP-3)
95 CD64 High affinity immunoglobulin gamma Fc receptor 0.263 0.225
I (Fc-gamma RI)
96 CD65 0.825 0
97 CD65s 7.62 0.539
98 CD66 Pregnancy-specific betaglycoprotein 1 PSGB1 0.474 0.737
99 CD66b 0.129 0
100 CD66c Carcinoembryonic antigen-related cell adhesion 23.4 7.33
molecule 6
101 CD66d Carcinoembryonic antigen-related cell adhesion 2.06 0.322
molecule 3
102 CD66e Carcinoembryonic antigen-related cell adhesion 56.1 13.6
molecule 5
103 CD69 Activation inducer molecule (AIM) 0.296 0.279
104 CD70 Tumor necrosis factor ligand superfamily 0.36 0.187
member 7 (TNFSF7)
105 CD71 Transferrin receptor protein 1 51 4.71
106 CD72 0.036 0.334
107 CD73 5'-nucleotidase/ SH3/SH4 100 99.8
108 CD74 HLA class II histocompatibility antigen gamma 0.177 0.587
chain
109 CD75 Beta-galactoside alpha-2,6-sialyltransferase 1 0.0789 0.304
110 CD77 Lactosylceramide 4-alpha-galactosyltransferase 7.15 2.4
111 CD79a B-cell antigen receptor complex-associated 15.4 0.45
protein alpha chain
112 CD79b B-cell antigen receptor complex-associated 4.87 0.317
protein beta chain
113 CD80 Activation B7-1 antigen 2.94 4.57
114 CD81 Tetraspanin-28 100 99.9
115 CD82 Tetraspanin-27 96.3 82.7
116 CD83 27.9 1.34
117 CD84 SLAM F5 7.94 4.1
118 CD85a Leukocyte immunoglobulin-like receptor 6.76 0.971
subfamily B member 3 (LIR-3)
119 CD85d Leukocyte immunoglobulin-like receptor 17 0.98
subfamily B member 3 (LIR-2)
120 CD85g Leukocyte immunoglobulin-like receptor 47.2 6.15
subfamily A member 4
121 CD85h Leukocyte immunoglobulin-like receptor 15.6 0
subfamily A member 2 (LILRA2)
122 CD85j Leukocyte immunoglobulin-like receptor 20.6 0.221
subfamily B member 1 (LIR-1)
123 CD86 24.7 0.702
124 CD87 Urokinase plasminogen activator surface receptor 0.178 1.61
(uPAR)
125 CD88 C5a anaphylatoxin chemotactic receptor 1 1.32 0.352
126 CD89 Immunoglobulin alpha Fc receptor 5.73 0.244
127 CD90 Thy-1 membrane glycoprotein 100 99.3
128 CD91 Prolow-density lipoprotein receptor-related 95.5 63.4
protein 1 (LRP-1)
129 CD92 Choline transporter-like protein 1 35.4 33.3
130 CD94 Natural killer cells antigen CD94 KLRD1 0.121 0.321
131 CD95 CD95L (Ligand) / Tumor necrosis factor ligand 98.9 66.7
superfamily member 6 (TNFSF6)
132 CD96 T-cell surface protein tactile 21 2.63
133 CD97 1.64 0.434
134 CD98 Large neutral amino acids transporter small 100 99.9
subunit 1
135 CD99 T-cell surface glycoprotein E2 24.8 0.224
136 CD100 Semaphorin-4D 0.103 0.132
137 CD101 Immunoglobulin superfamily member 2 (IgSF2) 0.29 0
138 CD102 ICAM-2 9.24 2.91
139 CD103 Integrin alpha-E (ITGAE) 0.152 0.297
140 CD104 Integrin beta-4 (ITGB4) 4.06 99.3
141 CD105 Endoglin (SH2) 99.9 100
142 CD106 VCAM 6.93 4.64
143 CD107a Lysosome-associated membrane glycoprotein 1 0.717 0.337
(LAMP-1)
144 CD107b Lysosome-associated membrane glycoprotein 2 0.221 0.225
(LAMP-2)
145 CD108 Semaphorin-7A 99.7 78
146 CD109 1.89 0.253
147 CD110 Thrombopoietin receptor (TPO-R) 55.6 16.6
148 CD111 Herpes virus entry mediator C 90.7 0
149 CD112 Poliovirus receptor-related protein 2 12.1 0.64
150 CD114 Granulocyte colony-stimulating factor receptor 54.9 4.83
(GCSFR/CSF3R)
151 CD115 Macrophage colony-stimulating factor 1 receptor 8.41 0
CSF-1 receptor (CSFR)
152 CD116 Granulocyte-macrophage colony-stimulating 17 2.61
factor receptor subunit alpha GM-CSF-R-alpha
153 CD117 Mast/stem cell growth factor receptor Kit (c-kit) 31.5 2.56
154 CD118 Leukemia inhibitory factor receptor (LIF-R) 67.4 0
155 CD119 Interferon gamma receptor 1 (IFNgammaR) 78.5 24.8
156 CD120a Tumor necrosis factor receptor superfamily 38.1 0
member 1A (TNFR1)
157 CD120b Tumor necrosis factor receptor superfamily 1.11 0.297
member 1B (TNFR2)
158 CD121b Interleukin-1 receptor type 2 (IL1R2) 39.8 2.75
159 CD122 Interleukin-2 receptor subunit beta (IL2RB) 41.7 4.56
160 CD123 Interleukin-3 receptor subunit alpha (IL3RA) 46.9 7.06
161 CD124 Interleukin-4 receptor subunit alpha IL4RA) 1.52 0.225
162 CD125 Interleukin-5 receptor subunit alpha (IL5RA) 19.5 0
163 CD126 Interleukin-6 receptor subunit alpha (IL-6R 1) 7.05 0.709
164 CD127 Interleukin-7 receptor subunit alpha (IL7RA) 18.5 12.5
165 CD129 Interleukin-9 receptor (IL9R) 0.178 0
166 CD130 Interleukin-6 receptor subunit beta (IL6ST) 83.6 8.15
167 CD131 Cytokine receptor common subunit beta 0.684 0
168 CD132 Cytokine receptor common subunit gamma 78.8 3.43
(IL2RG)
169 CD133 AC-133 (Prominin-1) 0.054 0
170 CD134 Tumor necrosis factor receptor superfamily 8.15 1.29
member 4 (TNFSF4)
171 CD135 Receptor-type tyrosine-protein kinase FLT3 5.18 0.575
172 CD136 Macrophage-stimulating protein receptor (MSP- 0.302 0
173 CD137 Tumor necrosis factor receptor superfamily 0.392 0
member 9 (TNFRSF9)
174 CD137L Mouse? 13.5 15.6
175 CD138 Syndecan-1 (SYND1) 0.227 0
176 CD140a Platelet-derived growth factor receptor alpha 4.1 0.98
(PDGFRA)
177 CD140b Platelet-derived growth factor receptor beta 89.1 97.8
(PDGFRB)
178 CD141 Thrombomodulin 21 0.385
179 CD142 Tissue factor / Thromboplastin 0.478 0.555
180 CD143 Angiotensin-converting enzyme (ACE) 29.3 0
181 CD144 Cadherin-5 0.0728 0.159
182 CD146 MUC18 94.2 89.5
183 CD147 Basigin 100 100
184 CD148 Receptor-type tyrosine-protein phosphatase eta 84.6 0
185 CD150 Signaling lymphocytic activation molecule 0.467 0.364
(SLAMF-1)
186 CD151 PETA-3 100 99.9
187 CD152 Cytotoxic T-lymphocyte protein 4 (CTLA-4) 6.45 5.87
188 CD153 Tumor necrosis factor ligand superfamily 10.9 1.19
member 8 (TNFSF8)
189 CD154 CD40 Ligand 0.357 0.893
190 CD155 Poliovirus receptor (PVR) 99.8 100
191 CD156b Disintegrin and metalloproteinase domain- 81 36.4
containing protein 17 (ADAM-17)
192 CD157 ADP-ribosyl cyclase 2/ Bone Marrow Stromal 0.713 6.33
Antigen 1 (BST-1)
193 CD158a Killer cell immunoglobulin-like receptor 2DL1 0.0919 0.22
194 CD158b Killer cell immunoglobulin-like receptor 2DL2 0.129 0.195
195 CD158b2 Killer cell immunoglobulin-like receptor 2DL3 2.54 0
196 CD158d Killer cell immunoglobulin-like receptor 2DL4 56.3 1.56
197 CD158e2 Killer cell immunoglobulin-like receptor 3DL1 0.254 0
198 CD158f Killer cell immunoglobulin-like receptor 2DL5A 25 0
199 CD158i Killer cell immunoglobulin-like receptor 2DS4 21.9 3.12
200 CD159a NKG2-A/NKG2-B type II integral membrane 6.57 0.462
protein (KLR-C1)
201 CD159c NKG2-C type II integral membrane protein 2.44 0.917
(KLR-C2)
202 CD160 1.07 0.9
203 CD161 Killer cell lectin-like receptor subfamily B 5.95 3.64
member 1 (KLRB1)
204 CD162 P-selectin glycoprotein ligand 1 (PSGL-1) 13.2 4.41
205 CD163 Scavenger receptor cysteine-rich type 1 protein 0.197 0
M130
206 CD164 Sialomucin core protein 24 (MUC-24) 11.9 27
207 CD165 0.716 3.55
208 CD166 Activated leukocyte cell adhesion molecule 99.9 99.8
209 CD167 Discoidin domain-containing receptor 2 (DDR2) 0.496 7.69
210 CD169 Sialoadhesin/ Siglec-1 1.76 0.178
211 CD170 Sialic acid-binding Ig-like lectin 5 (Siglec-5) 11.9 74.3
212 CD171 Neural cell adhesion molecule L1 (NCAM-L1) 1.9 0
213 CD172a Tyrosine-protein phosphatase non-receptor type 61.8 3.33
substrate 1 (SHP-1)
214 CD172b Signal-regulatory protein beta-1 (SIRP-beta-1) 0.0955 0.285
215 CD172g Signal-regulatory protein gamma (SIRP-gamma) 14.5 7.14
216 CD175s 96.2 27.1
217 CD177 Human neutrophil alloantigen 2a (HNA-2a) 0.477 0.46
218 CD178 CD95L (Ligand) / Tumor necrosis factor ligand 51.6 0.49
superfamily member 6 (TNFSF6)
219 CD179a 6.31 1.84
220 CD180 0.824 0.478
221 CD181 CXCR1 85 2.55
222 CD182 CXCR2 68.8 4.31
223 CD183 CXCR3 3.08 0
224 CD184 CXCR4 0.219 0.775
225 CD185 CXCR5 6.04 1.39
226 CD186 CXCR6 1.48 41.5
227 CD191 CCR1 12.6 0
228 CD192 CCR2 0.0662 0.0497
229 CD193 CCR3 51 8.16
230 CD194 CCR4 7.13 0
231 CD195 CCR5 1.02 1.94
232 CD196 CCR6 46.3 2.8
233 CD197 CCR7 0.159 0
234 CD200 OX-2 membrane glycoprotein (MOX-1) / (MOX- 0.594 0.912
235 CD201 Endothelial protein C receptor 55.7 0.858
236 CD202b Angiopoietin-1 receptor TIE2/TEK 82.7 23.2
237 CD203c Ectonucleotide 8.66 0
pyrophosphatase/phosphodiesterase family
member 3 (ENPP3)
238 CD204 Macrophage scavenger receptor types I and II 13.7 1.44
(MSR1)
239 CD205 Lymphocyte antigen 75 (Ly-75) 4.94 0
240 CD206 Macrophage mannose receptor 1 (MMR) 0.205 0
241 CD207 C-type lectin domain family 4 member K 0.0679 2.7
(Langerin)
242 CD208 Lysosome-associated membrane glycoprotein 3 3.27 0
(LAMP-3)
243 CD209 0.153 0
244 CD212 Interleukin-12 receptor subunit beta-1 (IL12RB1) 0.476 0.127
245 CD213a2 Interleukin-13 receptor subunit alpha-2 8.7 8
(IL13RA2)
246 CD215 Interleukin-15 receptor subunit alpha 14.6 0.86
247 CD217 Interleukin-17 receptor A (IL17RA) 29.8 35.8
248 CD218b Interleukin-18 receptor accessory protein (IL-18 23.4 0.463
R-beta)
249 CD220 Insulin Receptor IR 2.93 1.5
250 CD221 Insulin-like growth factor 1 receptor IGF-1R 3.16 1.1
251 CD222 Insulin-like growth factor 2 receptor IGF-2R 8.09 0.768
252 CD223 Lymphocyte activation gene 3 protein (LAG-3) 38.9 0
253 CD226 DNAX accessory molecule 1 (DNAM-1) 1.15 0.22
254 CD227 Mucin-1 (MUC-1) 4.87 5.79
255 CD229 T-lymphocyte surface antigen Ly-9 0.579 5.56
256 CD230 Major prion protein (PrP) 99.9 100
257 CD231 Tetraspanin-7 (TSPAN-7) 34.2 34.8
258 CD234 Duffy antigen/chemokine receptor (DARC) 7.7 0.397
259 CD235a Glycophorin-A 55.8 5.11
260 CD243 (BC) 20.8 2.31
261 CD243 (BD) 0.208 0
262 CD244 Natural killer cell receptor 2B4 0.548 0
263 CD245 99.2 13.3
264 CD249 Glutamyl aminopeptidase (EAP) 19.7 0
265 CD252 Tumor necrosis factor ligand superfamily 21.4 20.6
member 4 (TNFSF4)
266 CD253 Tumor necrosis factor ligand superfamily 44.1 7.07
member 10 (TNFSF10)
267 CD254 RANKL, TNFSF11 12.3 3.85
268 CD255 10.1 0.437
269 CD256 Tumor necrosis factor ligand superfamily 7.94 0.792
member 13 (TNFSF13)
270 CD257 Tumor necrosis factor ligand superfamily 63.2 5.03
member 13B (TNFSF13B)
271 CD258 Tumor necrosis factor ligand superfamily 3.17 0
member 14 (TNFSF14)
272 CD261 Tumor necrosis factor receptor superfamily 30.3 21.4
member 10A (TNFRSF10A)
273 CD262 Tumor necrosis factor receptor superfamily 12.1 4.55
member 10B (TNFRSF10B)
274 CD263 Tumor necrosis factor receptor superfamily 1.47 0
member 10C (TNFRSF10C)
275 CD264 Tumor necrosis factor receptor superfamily 44.9 9.09
member 10D (TNFRSF10D)
276 CD267 Tumor necrosis factor receptor superfamily 91.8 36.6
member 13B (TNFRSF13B)
277 CD268 Tumor necrosis factor receptor superfamily 64.6 13.5
member 13C / (BAFF-R)
278 CD269 Tumor necrosis factor receptor superfamily 8.51 2.4
member 17 (TNFRSF17)
279 CD270 Tumor necrosis factor receptor superfamily 31.6 8.79
member 14
280 CD271 Low-affinity nerve growth factor receptor 1.63 10.4
(NGFR)
281 CD272 B- and T-lymphocyte attenuator 33.2 12.3
282 CD273 Programmed cell death 1 ligand 2 92.4 51.7
283 CD274 Programmed cell death 1 ligand 1 23.9 1.12
284 CD275 ICOS Ligand 26 0.904
285 CD276 4Ig-B7-H3 100 97.8
286 CD277 Butyrophilin subfamily 3 member A1 1.55 0
287 CD278 Inducible T-cell costimulator 0.147 0.0836
288 CD279 Programmed cell death protein 1 5.5 0.492
289 CD281 Toll-like receptor 1 54.7 2.12
290 CD282 Toll-like receptor 2 0.101 0.529
291 CD283 Toll-like receptor 3 68.9 6.92
292 CD284 Toll-like receptor 4 7.94 0.84
293 CD286 Toll-like receptor 6 76.9 11.4
294 CD288 Toll-like receptor 8 85.6 11.2
295 CD289 Toll-like receptor 9 11.3 0.359
296 CD290 Toll-like receptor 11 45.1 9.5
297 CD292 Bone morphogenetic protein receptor type-1A 2.39 0.522
298 CD294 Prostaglandin D2 receptor 2 8.81 34.1
299 CD295 Leptin receptor (Lep-R) 49 73.7
300 CD298 Sodium/potassium-transporting ATPase subunit 99.8 98.9
beta-3
301 CD299 C-type lectin domain family 4 member M 29.5 1.07
302 CD300a CMRF35-like molecule 8 (CLM-8) 1.82 0.222
303 CD300c CMRF35-like molecule 6 (CML-6) 37.3 3.76
304 CD300e CMRF35-like molecule 2 (CML-2) 38.7 0.697
305 CD301 C-type lectin domain family 10 member A 3.39 0.626
306 CD303 C-type lectin domain family 4 member C 66.8 3.33
307 CD304 Neuropilin-1 (NRP-1) 65.2 0.502
308 CD305 Leukocyte-associated immunoglobulin-like 4.12 0.972
receptor 1 (LIAR-1)
309 CD307 7.08 0.305
310 CD309 VEGFR2 / FLK-1 / KDR 34.4 14.2
311 CD312 EGF-like module-containing mucin-like hormone 24.8 12.2
receptor-like 2
312 CD314 NKG2-D type II integral membrane protein 38.5 11.6
313 CD317 Bone Marrow Stromal Antigen 2 48.9 25
314 CD318 CUB domain-containing protein 1 71.7 12.3
315 CD319 SLAM family member 7 27.8 21.9
316 CD321 Junctional adhesion molecule A (JAM-A) 3.81 5.04
317 CD322 Junctional adhesion molecule B (JAM-B/2) 4.37 0.248
318 CD324 Cadherin-1 17.2 0.387
319 CD325 Cadherin-2 / N-cadherin 3.83 0.501
320 CD326 Epithelial cell adhesion molecule (EPCAM) 18.1 0.463
321 CD328 Siglec-7 32 1.99
322 CD332 FGFR2 0.814 0.181
323 CD333 FGFR3 7.78 1.01
324 CD334 FGFR4 1.35 1.76
325 CD335 NCR1 0.669 0.274
326 CD336 NCR2 0.544 0.212
327 CD337 87.3 26.4
328 CD338 ATP-binding cassette sub-family G member 2 49 19.5
329 CD339 Protein jagged-1 1.76 1.22
330 CD340 Receptor tyrosine-protein kinase erbB-2 94.9 41
331 CD344 Frizzled 4 65.5 17.5
332 CD349 Frizzled 9 87.6 80.3
333 CD351 FCAMR 76.4 28.1
334 CD352 SLAM-6 0.518 0.394
335 CD354 TREM-1 13.6 1.66
336 CD355 Cytotoxic and regulatory T-cell molecule 10.4 1.24
337 CD357 Tumor necrosis factor receptor superfamily 10.4 1.95
member 18
338 CD358/DR6 45.1 7.63
339 CD360 (BD) 24.9 3.53
340 CD360 (BL) 33 4.5
341 CD362 Syndecan-2 14.7 0.774
342 CD363 Sphingosine 1-phosphate receptor 1 18.7 0.757
343 CLA 0.277 9.23
344 CLIP 0.138 0
345 DCIR 0.264 0.15
346 EGF-R 33.3 2.02
347 FMC7 0.0776 0
348 HLA-ABC 99.9 99.8
349 HLA-A2 3.52 20.9
350 HLA-DM 0.172 0.14
351 HLA-DR 0.247 0.481
352 HPC 2.14 6.31
353 ITGB7 0.34 0.159
354 LTBR Tumor necrosis factor receptor superfamily 34.5 87.6
member 3
355 MIC A/B 97.1 0.328
356 Notch1 20.5 4.01
357 Notch2 95.8 22.8
358 Notch3 5.37 2.15
359 PAC-1 0.137 0.971
360 Podoplanin 8.81 2.91
361 SSEA-3 20.7 0.395
362 SSEA-4 87.4 2.44
363 Stro-1 18.5 6.27
364 TCR alpha 0.327 0.195
beta
365 TCR gamma 52.9 11.1
delta
366 TPBG 0.197 0.178
367 VB8 TCR 25.1 3.93
368 VD2 TCR 13.2 12.1
369 fMLP-R 11.4 0.641
Example 3 - Luminex assay
A luminex assay was used to quantitate different cytokines in the conditioned media from
Lonza cells and IMP cell cultures. Data is shown in pg/µg of RNA, this is to standardise the data
relevant to the number of cells in culture.
pg/ug RNA
Cytokine/Chemokine MSCs IMPs Result
IL-6 162.4 596 Increase
IL-8 6.9 59.8 Increase
IP-10 1.4 13.7 Increase
MCP-1 75.8 322.5 Increase
RANTES 1.07 125.3 Increase
IL-10 0.8 0.1 Decrease
IL-12 (p70) 41.6 21.9 Decrease
Claims (12)
1. A population of immuno-modulatory progenitor (IMP) cells, wherein (i) at least 90% of the cells in the population express on their surfaces detectable levels of MIC A/B, (ii) at least 60% of the cells in the population express on their surfaces detectable levels of CD304 (Neuropilin 1), (iii) at least 45% of the cells in the population express on their surfaces detectable levels of CD178 (FAS ligand), (iv) at least 10% of the cells in the population express on their surfaces detectable levels of CD289 (Toll-like receptor 9), (v) at least 15% of the population express on their surfaces detectable levels of CD363 (Sphingosinephosphate receptor 1), (vi) at least 20% of the cells in the population express on their surfaces detectable levels of CD99, (vii) at least 80% of the cells in the population express on their surfaces detectable levels of CD181 (C-X-C chemokine receptor type 1; CXCR1), (viii) at least 30% of the cells in the population express on their surfaces detectable levels of epidermal growth factor receptor (EGF-R), (xi) at least 60% of the cells in the population express on their surfaces detectable levels of CXCR2, and (x) at least 5% of the cells in the population express on their surfaces detectable levels of CD126, and wherein the IMP cells secrete detectable levels of interleukin-6 (IL-6) and interleukin-8 (IL-8).
2. A population according to claim 1, wherein (i) at least 97% of the cells in the population express on their surfaces detectable levels of MIC A/B, (ii) at least 65% of the cells in the population express on their surfaces detectable levels of CD304 (Neuropilin 1), (iii) at least 51% of the cells in the population express on their surfaces detectable levels of CD178 (FAS ligand), (iv) at least 11% of the cells in the population express on their surfaces detectable levels of CD289 (Toll-like receptor 9), (v) at least 18% of the population express on their surfaces detectable levels of CD363 (Sphingosinephosphate receptor 1), (vi) at least 24% of the cells in the population express on their surfaces detectable levels of CD99, (vii) at least 85% of the cells in the population express detectable levels of CD181 (CXCR1), (viii) at least 33% of the cells in the population express detectable levels of epidermal growth factor receptor (EGF-R), (ix) at least 68% of the cells in the population express detectable levels of CXCR2, and (x) at least 7% of the cells in the population express detectable levels of CD126.
3. A pharmaceutical composition comprising (a) a population according to claim 1 or 2 and (b) a pharmaceutically acceptable carrier or diluent, one or more liposomes and/or one or more microbubbles.
4. A method of producing a population of IMP cells according to claim 1 or 2, comprising (i) culturing mononuclear cells (MCs) for from 15 to 25 days in a medium comprising platelet lysate, at less than 20% oxygen (O ) and under conditions which allow the MCs to adhere to induce the MCs to differentiate into IMP cells and (ii) harvesting and culturing those IMP cells which have an expression pattern as defined in claim 1 and thereby producing a population according to claim 1, wherein the platelet lysate is produced by subjecting a population of human platelets to four freeze-thaw cycles, wherein the freeze portion of each cycle is carried out in liquid nitrogen.
5. A method according to claim 4, wherein: (a) the MCs are peripheral blood mononuclear cells (PBMCs) or primary MCs isolated from bone marrow; and/or (b) the MCs are obtained from a patient or an allogeneic donor.
6. Use of a population according to claim 1 or 2 or a pharmaceutical composition according to claim 3 in the manufacture of a medicament for repairing a damaged tissue in a patient or treating a cardiac, bone, cartilage, tendon, ligament, liver, kidney or lung injury or disease in a patient.
7. A use according to claim 6, wherein: (a) the damaged tissue is (i) derived from the mesoderm; (ii) is cardiac, bone, cartilage, tendon, ligament, liver, kidney or lung tissue; and/or (iii) is damaged by injury or disease; or (b) the cardiac injury or disease is selected from myocardial infarct, left ventricular hypertrophy, right ventricular hypertrophy, emboli, heart failure, congenital heart deficit, heart valve disease, arrhythmia and myocarditis, and/or the population is produced using MCs obtained from the patient or an allogeneic donor; or (c) the bone injury or disease is selected from fracture, Salter-Harris fracture, greenstick fracture, bone spur, craniosynostosis, Coffin-Lowry syndrome, fibrodysplasia ossificans progressive, fibrous dysplasia, Fong Disease (or Nail-patella syndrome), hypophosphatasia, Klippel-Feil syndrome, Metabolic Bone Disease, Nail-patella syndrome, osteoarthritis, osteitis deformans (or Paget's disease of bone), osteitis fibrosa cystica (or Osteitis fibrosa or Von Recklinghausen's disease of bone), osteitis pubis, condensing osteitis (or osteitis condensans), osteitis condensans ilii, osteochondritis dissecans, osteogenesis imperfecta, osteomalacia, osteomyelitis, osteopenia, osteopetrosis, osteoporosis, osteonecrosis, porotic hyperostosis, primary hyperparathyroidism, renal osteodystrophy, bone cancer, a bone lesion associated with metastatic cancer, Gorham Stout disease, primary hyperparathyroidism, periodontal disease, and aseptic loosening of joint replacements, and/or the population is produced using MCs obtained from the patient or an allogeneic donor.
8. A use according to claim 6 or 7, wherein the population is produced using MCs obtained from the patient or an allogeneic donor.
9. A population according to claim 1 substantially as herein described with reference to any example thereof.
10. A pharmaceutical composition according to claim 3 substantially as herein described with reference to any example thereof.
11. A method according to claim 4 substantially as herein described with reference to any example thereof.
12. A use according to claim 6 substantially as herein described with reference to any example thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1410504.3 | 2014-06-12 | ||
GBGB1410504.3A GB201410504D0 (en) | 2014-06-12 | 2014-06-12 | Immuno-modulaltory progenitor (IMP) cell |
PCT/GB2015/051673 WO2015189587A1 (en) | 2014-06-12 | 2015-06-09 | Immuno-modulatory progenitor (imp) cell |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ727129A NZ727129A (en) | 2021-02-26 |
NZ727129B2 true NZ727129B2 (en) | 2021-05-27 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2984163B1 (en) | Immuno-modulatory progenitor (imp) cell | |
US10829739B2 (en) | Progenitor cells of mesodermal lineage | |
US10316291B2 (en) | Immuno-oncology mesodermal progenitor (ioMP) cell | |
US20170119930A1 (en) | Hybrid composition | |
JP2023519647A (en) | Enhanced receptors that improve immune cell function | |
JP2022520777A (en) | An adjuvant capable of boosting the proliferation of immune cells in vivo | |
US12029763B2 (en) | Immuno-modulatory progenitor (IMP) cell | |
NZ727129B2 (en) | Immuno-modulatory progenitor (imp) cell | |
US20230047325A1 (en) | Mesodermal killer (mk) cell | |
WO2017168170A1 (en) | Immuno-modulatory progenitor (imp) cell expressing one or more of cd3, cd3e, cd8, cd8b, cd4, cd5, cd6 and cd7 | |
CN117460742A (en) | Materials and methods for enhanced stem cell-like memory T cell engineering |